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HSV-TK/GCV. It is hoped that the 
new enhanced treatment schedule for 
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ABSTRACT
Malignant glioma (MG) is the most common malignant brain tumor; its most malignant
form, glioblastoma multiforme has a dismal prognosis of ~14 months from diagnosis. Little
progress has been made with traditional therapies which consist of a combination of
surgery, radiotherapy and chemotherapy. MG is an ideal target for gene therapy due to its
spatially restricted localization and rarely metastasizing character. The aims of this thesis
were to develop novel gene therapy approaches as well as combination therapies in
preclinical in vitro and in vivo MG models.
     In the first study, Src kinase, a central signaling mediator of oncogenesis, was targeted
with lentiviral delivery of small hairpin RNAs (shRNAs). In subcutaneous nude mice
xenografts, the inhibition of Src was able to significantly reduce tumor growth and
vascularity, whereas in immunocompetent orthotopic rat MG model tumor growth
reduction and enhanced survival was only seen with ex vivo transduced tumors. A modest
in vivo therapeutic effect was seen in combination with a chemotherapeutic temozolomide
(TMZ) and a histone deacetylase inhibitor valproic acid (VPA).
     In the second study, adenoviral suicide gene therapy of Herpes simplex virus-1
thymidine  kinase  with  the  prodrug  ganciclovir  (HSV-TK/GCV)  was  combined  with  TMZ
and VPA. In vitro efficient viability reduction, enhanced transduction and bystander effect
were demonstrated. In vivo HSV-TK/GCV+TMZ improved the survival and reduced the
tumor growth of rats with orthotopic MG but VPA administration conferred no additional
benefit. An improved combination therapy schedule was also introduced.
     In the third study, HSV-TK/GCV therapy was compared with tomato thymidine kinase
combined  with  its  specific  prodrug,  azidothymidine  (ToTK/AZT).  Both  enzymes
demonstrated efficacy and substrate specificity in vitro but only mice receiving ToTK/AZT
had improved survival compared to non-treated control mice with intracranial MG. No
significant differences were observed between the two suicide gene therapies in vivo.
     In  conclusion,  Src  is  a  potential  target  for  gene  therapy  of  MG.  The  efficacy  of in vivo
therapy was hampered by the low transduction efficiency, which has been recognized as
one  of  the  major  challenges  in  gene  therapy.  Simultaneous  administration  of  GCV  with
TMZ further enhanced HSV-TK/GCV+TMZ efficacy being of potential value for MG
patients. Despite the conflicting findings in the literature, in the current experimental
setting, VPA was not able to achieve any further therapeutic benefits warranting for careful
optimization of the treatment schedule. ToTK/AZT was found to be an equally efficient
alternative for HSV-TK/GCV therapy with favorable therapeutic characteristics. In
summary, gene therapy is a potential therapeutic approach for MG although it requires a
carefully optimized treatment protocol.
National Library of Medicine Classification: QU 470, QU 550, QU 560, QZ 380
Medical Subject Headings: Glioma/therapy; Gene Targeting; Transduction, Genetic; Genetic Vectors; Genes,
Suicide; src-Family Kinases/antagonists & inhibitors; RNA, Small Interfering; Lentivirus; Adenoviridae;
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TIIVISTELMÄ
Maligni gliooma (MG) on yleisin pahanlaatuinen aivokasvaintyyppi, ja elinajanodote sen
pahimmanlaatuisen kasvaimen, glioblastooman, osalta on ainoastaan noin 14 kuukautta.
Perinteisesti käytetyistä leikkaushoidosta, sädehoidosta ja kemoterapiasta huolimatta
potilaiden ennuste on parantunut ainoastaan vähän viime vuosikymmeninä. MG sopii
hyvin geeniterapian kohteeksi paikallisen sijaintinsa ansiosta, minkä lisäksi sillä ei ole
taipumusta lähettää etäpesäkkeitä. Tämän väitöskirjatyön tavoitteena oli kehittää MG:an
uusia geenihoitoja ja niiden yhdistelmiä soluviljely- ja eläinkoemalleissa.
     Ensimmäisessä osatyössä syövän kannalta keskeistä Src kinaasia kohdennettiin
lentivirusvälitteisillä shRNA-molekyyleillä. Tällä hoidolla kyettiin rajoittamaan
ihonalaisten kasvainten kasvua sekä heikentämään niiden verisuonitusta
immuunipuutteisissa hiirissä. Immuunivasteeltaan normaalien rottien aivokasvaimissa
kyseinen hoito yksinään ei ollut tehokas, mutta sen tehoa pystyttiin hieman parantamaan
liittämällä siihen kemoterapialääke temozolomidi (TMZ) sekä histonideasetylaasiestäjä
valproaatti (VPA).
     Toisessa osatyössä hyödynnettiin Herpes simplex virus-1 tymidiinikinaasin ja aihiolääke
gancicloviirin (HSV-TK/GCV) itsemurhageeniterapiaa. Tämä geeniterapia yhdistettiin
TMZ:iin ja VPA:iin. Solukokeissa hoito oli tehokas parantaen solujen transduktiotehoa sekä
myös hoitovastetta viereisissä soluissa. HSV-TK/GCV+TMZ-hoito pienensi rottien
aivokasvaimia pidentäen myös elinaikaa merkittävästi. VPA:lla ei saatu hoitovastetta.
Kyseisessä osatyössä parannettiin myös yhdistelmäterapian aikataulua.
     Kolmannessa osatyössä HSV-TK/GCV-terapiaa verrattiin tomaatin tymidiinikinaasi ja
aihiolääke azidotymidiini (ToTK/AZT) -hoitoon. Solukokeissa molemmat hoidot
osoittautuivat tehokkaiksi ja kinaasit aihiolääkkeilleen spesifisiksi. Hiirten
aivokasvainmallissa ainoastaan ToTK/AZT-hoidolla oli hiirten elinaikaa merkittävästi
pidentävä vaikutus verrattuna kontrollihiiriin. Hoitojen välillä ei todettu merkittävää eroa.
     Yhteenvetona voidaan todeta Src kinaasin olevan keskeinen malignin gliooman
geeniterapiakohde, vaikkakin eläinmalleissa hoitotehoa rajoittaa matala transduktioteho,
jonka on todettu olevan yksi geeniterapian suurimpia haasteita. GCV:n ja TMZ:n
yhtäaikainen annostelu tehosti HSV-TK/GCV+TMZ-hoitoa, mistä saattaisivat hyötyä myös
MG potilaat. Ristiriitaisesta kirjallisuudesta huolimatta kyseisessä tutkimuksessa VPA:sta ei
saatu lisähyötyä, mikä korostaa tutkimusasetelman tarkan optimoinnin tärkeyttä.
ToTK/AZT osoittautui mahdolliseksi vaihtoehdoksi HSV-TK/GCV-hoidolle edullisten
ominaisuuksiensa ansiosta. Geeniterapian voidaan todeta olevan potentiaalinen malignin
gliooman hoitomuoto hoitoprotokollan ollessa tarkkaan optimoitu.
Luokitus: QU 470, QU 550, QU 560, QZ 380
Yleinen Suomalainen asiasanasto: aivokasvaimet; glioomat; geeniterapia; geenitekniikka; lentivirukset;
adenovirukset; koe-eläimet
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“If we knew what it was we were doing, it would not be called research, would it?”
- Albert Einstein -
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1 Introduction
According to World Health Organization (WHO) cancers are significant causes of death
worldwide with 8.2 million cancer deaths in 2012 while 14.1 million new cancer cases were
diagnosed in the same year (Stewart, Wild 2014). Malignant gliomas (MGs) are the most
common malignant primary brain tumors; the most malignant of these tumors,
glioblastomas (GBMs), have a prognosis of less than 15 months with standard treatment
(Omuro, DeAngelis 2013, Stupp et al. 2014). The standard treatment consists of a
combination of surgery, radiotherapy and chemotherapy, but it is merely palliative in the
case of GBM (Stupp et al. 2005, Stupp et al. 2009). The efficacy of the current treatment
strategies  is  limited  by  the  toxicity  associated  with  radio-  and  chemotherapy,  and  the
invasive nature of GBM preventing the total resection of tumor. Therefore novel
therapeutic approaches are urgently needed.
In gene therapy, genetic material is delivered into a target cell with the intent of
achieving  a  therapeutic  outcome.  Most  of  the  gene  therapy  clinical  trials  are  being
undertaken against cancer and this is reflected in the broad spectrum of therapeutic targets
(Wirth, Parker & Yla-Herttuala 2013). Src is a tyrosine kinase located downstream of several
growth factor receptors mediating a wide spectrum of cellular functions. Src has been
shown to be important for oncogenesis and thus it is a major therapeutic target of MG
(Ahluwalia et al. 2010, Alvarez, Kantarjian & Cortes 2006). In this thesis, lentiviral delivery
of  shRNAs  was  used  to  achieve  Src  inhibition.  The  most  widely  studied  suicide  gene
therapy based on Herpes simplex virus-1 thymidine kinase and prodrug ganciclovir (HSV-
TK/GCV) was combined with the first-line chemotherapeutic agent for MG, temozolomide
(TMZ). This treatment was further combined with valproate (VPA), a histone deacetylase
inhibitor previously shown to enhance gene therapy, radiotherapy and chemotherapy (Fan
et al. 2005, Van Nifterik et al. 2012). VPA is an anticonvulsant drug which has long been
utilized in MG patients (Loscher 1999, Chateauvieux et al. 2010). HSV-TK/GCV therapy was
also compared with a novel suicide gene therapy of tomato thymidine kinase combined
with a prodrug azidothymidine (ToTK/AZT). AZT has been shown to easily penetrate
blood brain barrier (BBB) improving tumor accessibility (Denny 2003).
The aim of this thesis was to assess the aforementioned therapeutic strategies and their
combinations in vitro and in vivo in  preclinical  MG  models.  The  overall  purpose  of  these
experiments was to gain knowledge to further develop and optimize treatments for MG.
2
32 Review of literature
2.1 CANCER
Cancer is a major cause of death all around the world with an increasing incidence as the
individual ages. It is the leading cause of death in the developed countries and the second
most  common  in  the  developing  countries  (Umar,  Dunn  &  Greenwald  2012).  Tumors,
manifestations  of  cancer,  can  be  classified  as  being  either  benign  or  malign.  The  primary
tumor exists at the site of occurrence while malign tumors have the capability of sending
metastases to distant locations in the body. It is these metastases which are the cause of
cancer deaths in over 90 % of the cases (Hanahan, Weinberg 2011, Sporn 1996).
Independent of tissue of origin, malignant tumors display certain common characteristic
alterations in their physiological behavior, the so called hallmarks of cancer (Figure 1).
These include self-sufficiency in growth signals, insensitivity to antigrowth signals,
resistance to cell death, limitless replicative potential, sustained angiogenesis, and tissue
invasion and metastasis. In addition to these well-established hallmark characteristics,
more recently deregulation of cellular energetics and avoidance of immune destruction
have been proposed as emerging hallmarks. In order to acquire these hallmarks, the
concept of tumor enabling characteristics, namely genomic instability and tumor-
promoting inflammation, has been established. (Hanahan, Weinberg 2000, Hanahan,
Weinberg 2011)
Figure 1. Hallmarks of cancer. The eight hallmarks and two enabling characteristics (genome
instability & mutation and tumor-promoting inflammation) of cancer. Modified from Hanahan &
Weinberg 2011.
42.2 MALIGNANT GLIOMA
2.2.1 Epidemiology and etiology
Malignant gliomas (MGs) are the most common type of malignant brain tumors. The yearly
incidence is ~3-5/100 000 with a slight male predominance and peak incidence in the fifth
and sixth decades of life (Stupp et al. 2014). There is a tendency towards higher incidence
rates in the highly developed, industrialized countries (Ohgaki, Kleihues 2005a). In the
Finnish population, 950 primary central nervous systems (CNS) tumors were diagnosed in
2009, 40 percentage of these being gliomas (Joensuu et al. 2013). Most tumors develop in the
cerebral hemispheres and have an unknown etiology. The only well-known risk factor is a
previous course of radiotherapy. In addition, some rare genetic disorders,  for example Li-
Fraumeni syndrome and neurofibromatosis, are thought to be associated with 5 % of brain
cancers.  MG  does  not  seem  to  show  any  clear  associations  with  diet,  smoking,
environmental factors or viruses (Ohgaki, Kleihues 2005a).
2.2.2 Classification and grading
Tumors of the CNS, including MGs, are histopathologically heterogeneous. The latest
WHO classification of CNS tumors dates from 2007 (Table 1). Tumors are given histological
grades from I to IV reflecting their biological behavior (Table 2) and the grading influences
the choice of therapies, particularly the use of adjuvant radiation and specific
chemotherapy (Louis et al. 2007, Maenpaa 2010). Grade I and II tumors are considered as
low-grade whereas grades III and IV represent high-grade tumors. MGs belong to grades
III and IV. Glioblastoma (multiforme) (GBM) is a grade IV tumor accounting for ~80 % of
MGs. It is characterized by high cellularity and mitotic activity, vascular proliferation and
necrosis (Omuro, DeAngelis 2013).
Table 1. The most common gliomas
Tumor based on cell origin Grade Histological appearance
Astrocytoma
II Astrocytoma
III Anaplastic astrocytoma
IV Glioblastoma (multiforme) (GBM)
Oligodendroglial glioma
II Oligodendroglioma, oligoastrocytoma
III Anaplastic oligodendroglioma, anaplastic oligoastrocytoma
(IV Glioblastoma with oligodendroglial component)
Modified from Louis et al. 2007 and Maenpaa 2010.
5Table 2. Characteristics of different brain tumor grades
Grade Characteristics
I
Benign tumor with slow growth, defined margins, often operable, does not infiltrate brain
parenchyma, prognosis good if tumor is fully removed
II
Infiltrating brain parenchyma and cannot normally be fully removed, tendency to recur and
progress to higher grades
III
Infiltrating brain parenchyma and cannot normally be fully removed, margins undefined, high
tendency to recur, histological evidence of malignancy
IV
Infiltrating brain parenchyma and cannot normally be fully removed, histological and
cytological evidence of malignancy, fast progression, fatal outcome
Modified from Louis et al. 2007.
2.2.3 Pathogenesis and molecular biology
Tumors  of  MG  originate  from  the  CNS  supportive  glial  cells  or  their  precursors,  neural
stem cells. They are not only pleomorphic in terms of size and shape, but also highly
heterogeneous from a molecular standpoint (Tanaka et al. 2013). On the other hand, as
shown by The Cancer Genome Atlas (TCGA) project, there are common genetic alterations
in the three main signaling pathways in most GBMs: receptor tyrosine kinase (RTK), Ras,
phosphoinositide-3 kinase (PI3K) (88%); P53 (87%) and retinoblastoma protein (Rb) (78%)
(Cancer Genome Atlas Research Network 2008). Primary GBMs develop without a previous
lesion (de novo)  and  account  for  most  tumors  in  older  patients.  Secondary  GBMs,  on  the
other hand, are more likely to occur in younger patients and progress from a pre-existing
lower-grade glioma. Primary and secondary GBMs differ also significantly in their genetic
profiles (Nobusawa et al. 2009).
The MG types of tumors have been divided into 4 subclasses: classical, mesenchymal,
proneural and neural, based on their transcriptional profile (Verhaak et al. 2010). Recently it
has been acknowledged that different subclasses can exist even within a single tumor,
therefore affecting the choice of an individual therapy and the treatment outcome (Patel et
al. 2014, Sottoriva et al. 2013). The classical subtype displays the most common genetic
aberrations in GBM, namely chromosome 7 amplification and 10 deletion, epidermal
growth factor receptor (EGFR) amplification and Ink4a/ARF locus spanning deletion.
Characteristic to the mesenchymal subtype is prominent necrosis and the associated
inflammation,  high  expression  of  CHI3L1  and  MET  as  well  as  neurofibromin  1  (NF1)
mutations/deletion and low level of NF1 mRNA expression. The proneural subtype has
been associated with younger age of patients and most secondary GBMs are classified as
proneural. Abnormalities in platelet-derived growth factor receptor-A (PDGFR-A),
isocitrate dehydrogenase (IDH) and mutations in TP53 are characteristics encountered with
this subtype. The neural subtype has expression patterns rather resembling normal brain
tissue indicative of a differentiated cell phenotype (Murat et al. 2008, Verhaak et al. 2010,
Phillips et al. 2006). While this subtyping may help to understand the pathogenesis of GBM,
and to develop new diagnostic assays as well as assisting in the choice of different
therapeutic approach, it also emphasizes the vast molecular pathogenesis underlying MG.
(Colman, Aldape 2008, Huse, Holland 2010)
Clinically significant molecular markers include genetic loss on chromosomes 1p/19q,
mutations of IDH and methylation of O6-methylguanine-DNA methyltransferase (Mgmt)
gene promoter. Co-deletion, resulting in loss of heterozygosity (LOH) 1p/19q, is caused by
6the chromosomal translocation often seen in oligodendrogliomas. This results in increased
sensitivity to radio- and chemotherapy and prolonged survival of patients. IDH mutations
are  common  in  low-grade  gliomas  and  are  associated  with  a  better  prognosis.  The
observation of IDH mutations in higher-grade gliomas suggests that they have developed
from a lower grade precursor tumor. Epigenetic silencing of the Mgmt promoter by
methylation proposes weakened cellular repair capacity towards DNA damage (Hegi et al.
2008). In retrospective analyses, this property was found to be correlated with a beneficial
response to alkylating agent chemotherapy (Hegi et al. 2005, Reifenberger et al. 2012). The
need for analyses of Mgmt methylation status is however dependent on the diagnostic and
therapeutic context of an individual patient, and it has not been shown to vary within the
molecular subclasses of MGs (Verhaak et al. 2010). However, it has been shown to be an
important biomarker of treatment in the elderly (Malmstrom et al. 2012, Wick et al. 2012).
Other molecular markers include GBM-associated epidermal growth factor receptor variant
III (EGFRvIII) which is a possible biomarker for vaccination. (Stupp et al. 2014, Weller et al.
2013, Thon, Kreth & Kreth 2013, Louis 2006)
2.2.4 Clinical features and diagnostics
The symptoms of a patient with MG depend largely on tumor location, its size and growth
speed. Increased intracranial pressure can cause general symptoms whereas local
symptoms are related to anatomical tumor location via infiltration and/or compression of
normal brain structures. The most typical first symptom is an epileptic seizure and the life-
time risk for this symptom is in the range of 30-50 % (van Breemen, Wilms & Vecht 2007).
New-onset persistent or recurrent headache, nausea and vomiting, problems with vision as
well as various cognitive problems also warrant further examination of the patient.
Cognitive problems may include problems in memory functions, deduction, observation,
ability to concentrate and maintain attention. In addition, aphasia, hemiparesis and urinary
incontinence may be encountered. (Omuro, DeAngelis 2013)
The diagnosis  of  MG is  based on histopathology complemented with imaging findings
(Figure 2). Most often computer tomography (CT) is the primary imaging method due to its
widespread availability, but magnetic resonance imaging (MRI) is the most accurate and
versatile, especially when imaging the spinal cord or hypophysis (Omuro, DeAngelis 2013).
In addition, obtaining a histological sample from the tumor, usually taken during surgery,
is crucial for planning the treatment and follow-up. Primary CNS tumors, including MGs,
rarely metastasize elsewhere in the body, but can spread within CNS. Therefore the
evaluation of the proliferation index from histological sample helps to estimate the growth
potential and further to select the most appropriate treatment (Joensuu et al. 2013).  The
response to treatment as well as differential diagnosis between tumor recurrence and
treatment-induced unspecific changes may be clarified further by undertaking magnetic
resonance spectroscopy, positron emission tomography or single-photon emission
computed tomography with a tracer (Stupp et al. 2014, Minn 2005).
7Figure 2. Appearance of GBM in MRI and histology. Axial T1-weighted MRI without (A) and with
(B) gadolinium contrast agent demonstrating a GBM tumor in the right temporal lobe. The
cystic/necrotic  core of  the tumor is  well  illustrated in figure 2B as well  as in 2C revealing the
histological appearance of GBM. The necrotic core of the tumor is marked with an asterisk (C).
High cellularity and endothelial proliferation are seen surrounding the capillaries. The tumor in C
is from a different patient from figures A and B. Modified from Omuro & DeAngelis 2013 (A and
B) and www.solunetti.fi (C).
2.2.5 Treatment
There is no curative treatment for MG. The standard care of a patient with MG consists of a
combination of surgery, radiotherapy and chemotherapy. Concomitant and adjuvant TMZ
chemotherapies  in  addition  to  radiotherapy  are  the  current  standard  of  care  for  GBM
patients up to age 70 (Stupp et al. 2005, Stupp et al. 2009), even older if fit (Gilbert et al.
2013). This has significantly improved the median survival (benefit of 2.5 months in
comparison to radiotherapy only). The location and size of a tumor, primary therapy versus
recurrent disease and overall situation of a patient including age, health condition and
other diseases are some of the factors affecting the choice of the therapy. Symptoms of a
patient and life estimate are also factors that need to be considered. Treatment is planned
individually, but although the aim might be permanent recovery, often the best that can be
achieved is either slowing down the disease progression or minimizing the injurious effects
caused by the tumor and the treatments (Joensuu et al. 2013). With GBM, almost all patients
will experience a recurrent disease manifested as a local progression usually within 2-3 cm
margins from the original tumor area after 7-10 months progression free survival (PFS).
Systemic therapy is considered essential for recurrent tumors. Nevertheless, post-
recurrence survival is commonly only 6-9 months (Thon, Kreth & Kreth 2013).
2.2.5.1 Surgery
When applicable, surgery with full or partial resection is the primary mode of treatment.
An emergency operation is only needed when there is a massive hydrocephalus or a tumor
is very large. A histological sample is taken during the surgery and the cryosection can be
analyzed immediately to decide on the resection margins. If the tumor is small and located
deep in the brain, a stereotactic biopsy can be taken and analyzed prior to possible surgery.
The  anatomy  of  nearby  brain  structures  and  physiological  functions  of  brain  areas  are
evaluated and necessary imaging conducted before the surgery. Assisting equipment such
as a stereotactic device or neuronavigator may be used in the operation. The use of the
fluorescent marker, 5-amino-laevulinic acid (5-ALA), has been shown to increase the
8complete resection rate as well as improving PFS (Stummer et al. 2006). Complete removal
of the tumor is the clinical goal with non-malignant, grade I gliomas which have well
defined margins. However, with grade II-IV tumors, surgical resection is almost always
partial and suboptimal, and therefore further treatment with radio- and chemotherapy
often will be necessary (Joensuu et al. 2013). Postoperative imaging with MRI should be
done within a couple of days to evaluate the extent of resection and residual disease. With
recurrent MG, survival benefits of surgical resection are unclear, but it can be used to
relieve the symptoms caused by the tumor mass, cytoreduction and update of tumor
characteristics (Omuro, DeAngelis 2013). Only approximately one in every four patients has
a recurrent GBM tumor, which is amenable to repeated surgery (Mandl et al. 2008).
2.2.5.2 Radiotherapy
Radiotherapy (RT) is given either as an adjuvant treatment after the surgery or as a stand-
alone option for inoperable tumors. RT can also be used to alleviate the symptoms caused
by the tumor as a palliative treatment. It is usually given over 5-6 weeks up to 60 Gy total
dose in 1.8-2.0 Gy fractions (Joensuu et al. 2013). Doses beyond 60 Gy have not been found
to offer any additional benefits (Stupp et al. 2014). Shorter, hypo-fractionated regimens may
be beneficial for elderly patients or patients with a low performance status (Malmstrom et
al. 2012). Furthermore, elderly patients with an unmethylated Mgmt promoter should be
treated with RT alone (Malmstrom et al. 2012, Wick et al. 2012). Pseudoprogression is a
phenomenon seen usually 4-12 weeks after RT in 20-30 % of patients with increased tumor
size and a mass effect corresponding to RT effects rather than treatment failure (de Wit et
al. 2004, Wen et al. 2010). The common practice is to continue the ongoing treatment with
close imaging follow-up, and to attempt to alleviate any possible symptoms suffered by the
patient (Omuro, DeAngelis 2013, Stupp et al. 2014). For recurrent MG, several technically
different radiation approaches are available: fractionated 3D-conformal-, fractionated
stereotactic and hypofractionated stereotactic/radiosurgical approaches have been used
(Combs, Debus & Schulz-Ertner 2007). There are some other less extensively used
alternatives for example brachytherapy, radio-immunotherapy and boron neutron capture
therapy (BNCT) (Niyazi et al. 2011, Joensuu et al. 2003). However, re-irradiation is an
option only for selected patients due to the increased risk of radiation-evoked brain injury
and cognitive side effects due to large, cumulative doses (Juratli, Schackert & Krex 2013).
2.2.5.3 Chemotherapy
TMZ is an alkylating agent which adds methyl groups to the O6-position of guanine. It  is
the  first  line  chemotherapy  for  MG  and  can  be  given  concomitantly  with  RT  following
surgery, as an adjuvant therapy as well as in palliative care. When it  has been given both
concomitantly and in the adjuvant phase for primary GBM, it has been shown to increase
OS as well as PFS when compared to radiotherapy alone (Hart et al. 2013). TMZ has good
BBB penetration, and the treatment efficacy is based on the prevention of replication by
crosslinking  DNA.  It  is  orally  administered  at  doses  of  75  mg/m2/day daily during
radiotherapy and 150-200 mg/m2/day on five consecutive days in six cycles of 28 days as an
adjuvant treatment (Stupp et al. 2014, Stupp et al. 2005). The most common toxicities
associated with the drug are neutropenia and thrombocytopenia. Mgmt gene promoter
methylation has proved to be the strongest prognostic marker for treatment outcome, and
the benefit of TMZ chemotherapy is largely restricted to this patient subgroup (Hegi et al.
92005). There have been attempts to improve the efficacy with dose-dense TMZ regimens
(for example 21-of-28-days schedule) which aim at reducing MGMT levels and therefore
exhausting its repair activity. However, these trials have not demonstrated improved
efficacy with dose-dense regimens indicating that it is peak TMZ concentrations, rather
than prolonged exposure, which seems to be crucial for treatment efficacy (Gilbert et al.
2013, Brada et al. 2010).
Carmustine  (BCNU)  containing  biodegradable  polymers  is  another  US  Food  and  Drug
Administration (FDA) approved agent for the first-line treatment of MG (Lin, Kleinberg
2008). These can be implanted into the tumor cavity after tumor resection resulting in a
modest survival benefit as compared with radiotherapy alone (Westphal et al. 2003).
However, in the setting of recurrent MG, no additional benefit was observed either in terms
of PFS or quality of life (QoL) (Hart et al. 2008). Other chemotherapeutics used in MG
include for example a combination of procarbazine, lomustine and vincristine (PCV),
carboplatin and irinotecan (Omuro, DeAngelis 2013, Stupp et al. 2014).
For recurrent MG, the salvage chemotherapy options include TMZ re-challenge, other
alkylating agents (e.g. nitrosoureas and carboplatin) or bevacizumab (Omuro, DeAngelis
2013). Carmustine and lomustine (CCNU), belonging to the nitrosoureas, were previously
traditional treatment options for recurrent tumors. However, their efficacy is modest and
the risk of hematotoxicities is high (Batchelor et al. 2013). In recurrent GBM, TMZ has not
been shown to improve OS in comparison to radiotherapy (Hart et al. 2013) and neither did
PCV, although PFS and QoL were significantly improved with TMZ as compared to PVC
(Brada et al. 2010). It has been reported that relapsing low-grade astrocytoma, anaplastic
astrocytomas and oligodendrogliomas are more likely than GBM to respond to TMZ (Yung
et al. 1999). The treatment efficacy is generally compromised by the chemoresistance of
GBM cells, systemic toxicities and the limited bioavailability of most of these drugs in CNS
(Thon, Kreth & Kreth 2013).
2.2.5.4 Other treatments
In addition to surgery, radiotherapy and chemotherapy, symptomatic medication is a part
of the standard treatment of MG patients; e.g. corticosteroids for tumor-associated edema
and anticonvulsants to prevent seizures (Omuro, DeAngelis 2013). New alternative
treatment modalities are constantly being developed. MG vaccination strategies will be
discussed in more detail in the immunotherapy chapter 2.3.3.3. A novel therapeutic
approach using aligned polymeric nanofibers to guide intracortical brain tumor cells to an
extracortical cytotoxic hydrogel was recently described for the treatment of inoperable
tumors (Jain et al. 2014).
2.2.5.4.1 Targeted therapies
The  pathology  and  gene  expression  of  MGs  are  extremely  heterogenous  even  within  a
single  tumor,  and  therefore  various  therapeutic  modalities  such  as  antibodies  and  kinase
inhibitors have been developed against several different targets (Rich, Bigner 2004,
Sathornsumetee et al. 2007). Small molecule kinase inhibitors have been some of the most
widely studied approaches with the main kinase targets being EGFR, mammalian target of
rapamycin (mTOR), vascular endothelial growth factor receptor-2 (KDR/VEGFR-2),
vascular endothelial growth factor receptor-1 (FLT1/VEGFR-1), protein kinase C beta
(PKC) and platelet-derived growth factor receptor (PDGFR). Some of these have reached
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clinical trials up to phase III, but the results so far have not been so impressive to warrant
any change in standard clinical practice (De Witt Hamer 2010). A few examples of targeted
therapies will be discussed below.
Since  the  treatment  response  of  TMZ  is  strongly  correlated  with  Mgmt  gene  promoter
methylation, alternative treatment strategies for patients with unmethylated Mgmt have
been sought. Bevacizumab (Avastin®), a humanized murine vascular endothelial growth
factor A (VEGF-A) monoclonal antibody, has FDA approval for the treatment of recurrent
GBM. Bevacizumab inhibits VEGF-A binding to its receptors and this results in down-
regulation of angiogenesis, a prominent feature in GBM (Ferrara, Hillan & Novotny 2005).
Recently,  in  two  phase  III  trials,  bevacizumab  was  shown  to  improve  PFS  by  3.4  and  4.4
months as compared to placebo group in newly diagnosed GBM. However, neither trial
demonstrated any improvement in OS and adverse events, such as a neurocognitive
decline, were attributed to bevacizumab (Chinot et al. 2014, Gilbert et al. 2014). The over-
expression of EGFR and its amplification are prominent features in approximately half of
the GBMs. Therefore different approaches to inhibit EGFR have been investigated: two
small molecular inhibitors, erlotinib and gefitinib, the monoclonal antibody cetuximab and
their combinations. However, these approaches have mainly shown efficacy in subsets of
MG patients. (Schwer et al. 2008, Preusser et al. 2008, Neyns et al. 2009, de Groot et al. 2008,
Prados et al. 2006, Wen et al. 2014)
Cilengitide is an example of a targeted treatment approach for newly diagnosed GBM
that has reached phase III. Cilengitide is a selective peptide antagonist of v integrin
receptors and these receptors which are expressed on endothelial cells and tumor cells in
GBM transmit signals for angiogenesis, attachment, migration, invasion and viability
(Maurer et al. 2009, Schnell et al. 2008). Cilengitide therapy was shown to improve PFS and
OS in a phase I/IIa study (Stupp et al. 2010). However, although being well-tolerated,
Cilengitide failed to prolong PFS or OS in a phase III multicenter study (Stupp et al. 2013).
CooP is another, more recently discovered tumor homing peptide, which was shown to
reduce  the  number  of  tumor  satellites  in  the  brain  when  conjugated  with  the
chemotherapeutic agent, chlorambucil. It was therefore postulated to target the invasive
tumor cells by functioning as a drug carrier for otherwise difficult-to-reach tumor areas
(Hyvonen et al. 2014).
2.2.5.4.2 Histone deacetylase inhibitors, Valproic acid
Epigenetic mechanisms are important regulators of gene functions and they have been
shown to be involved also in MG development and progression (Nagarajan, Costello 2009).
One of the functional regulators is histone acetylation, which is the result of the balance
between histone acetyltransferases (HATs) and histone deacetylases (HDACs). Acetylation
of histones by HATs promotes the appearance of open chromatin and active transcription
whereas HDACs function as transcriptional repressors by deacetylating histones (Beumer,
Tawbi 2010). Thus histone deacetylase inhibitors (HDIs) promote hyperacetylation and
alter gene expression by inhibiting HDACs, an event which has been shown to preferably
occur in transformed cells as compared with normal cells (Karagiannis, El-Osta 2006).
HDIs  have  been  shown  to  modulate  tumor  angiogenesis,  immunogenicity,  invasion,
metastasis, differentiation, proliferation and apoptosis (Bolden, Peart & Johnstone 2006,
Berendsen et al. 2012). These compounds sensitize cancer cells to radiation and DNA
damaging  agents,  for  example  chemotherapeutics,  by  promoting  open  chromatin  and
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repressing DNA damage response by prolonging the expression of damage response
markers (Chen et al. 2007). Therefore, they have emerged as a new class of potential anti-
cancer compounds. HDIs have been shown to alter, both up- and down-regulate, possibly
over 20 % of the transcriptome in a cell type-specific manner (Chateauvieux et al. 2010,
Gotfryd et al. 2010). Their functions have been only partially elucidated and some of them
have also impaired the efficacy of drug therapy such as the increased expression of multi-
drug resistance proteins leading to increased cellular efflux of chemotherapeutics (Kim et
al. 2008, Tabe et al. 2006).
Valproic acid (VPA) is a HDI belonging to the class of short chain fatty acids (Beumer,
Tawbi 2010). It has traditionally been used as an anticonvulsant for epileptic seizures
(AED), also for MG patients, and as a mood-stabilizer in bipolar disorders (Chateauvieux et
al. 2010, Loscher 1999). VPA, and its sodium salt valproate, have been shown to upregulate
coxsackie-adenovirus receptor (CAR) (Segura-Pacheco et al. 2007), enhance transduction
efficiency (Stedt et al. 2013) as well as upregulate transgene expression (Fan et al. 2005).
VPA has been reported to sensitize glioma cells to radiation and TMZ without antagonizing
its effect (Van Nifterik et al. 2012). The latter is mediated by downregulation of Mgmt
expression  in  TMZ-resistant  cells  (Ryu  et  al.  2012).  Patients  receiving  VPA  with  TMZ/RT
were shown to have an improved survival compared to those treated with other AEDs or
no AEDs in the EORTC/NCIC phase III trial (Weller et al. 2011). Furthermore, the improved
survival with VPA together with RT (Barker et al. 2013) or TMZ/RT has been demonstrated
(Kerkhof et al. 2013). However, contradictory results have also been obtained (Tsai et al.
2012, van Breemen et al. 2009) and the discrepancies will need to be clarified in further
prospective studies.
2.2.6 Prognosis
The prognosis of a patient with MG is influenced not only by clinical findings such as age
of the patient, neurologic performance status and tumor location but also other factors i.e.
radiological features such as contrast enhancement, extent of surgical resection,
proliferation indices and genetic alterations. In addition, tumor grade is a key factor when
predicting the therapeutic response and outcome of a patient (Louis et al. 2007). An older
age of an MG patient has been associated with shorter survival at the population level
(Ohgaki, Kleihues 2005b). Aggressive treatment was shown to significantly reduce the
mortality in classical and mesenchymal subtypes and was claimed to do so in neural type
tumors. However, survival was not altered in the proneural subtype (Cancer Genome Atlas
Research Network 2008, Murat et al. 2008, Verhaak et al. 2010). One of the reasons for poor
treatment response may be the presence of glioma stem cells (GSC) in tumors (Singh et al.
2004). Although their role in MG is still controversial, GSCs have been shown to be resistant
to the conventional therapies, i.e. radiotherapy (Bao et al. 2006) and chemotherapy (Liu et
al. 2006).
MG has a poor prognosis: historically the median survival of patients on supportive care
has been only ~14 weeks (Avgeropoulos, Batchelor 1999). This was increased to ~20 weeks
with  surgery  only  and  further  up  to  7-12  months  with  post-operative  RT  (Avgeropoulos,
Batchelor 1999, Laperriere et al. 2002). Chemotherapy (mainly with nitrosoureas at the time)
increased the median survival up to 12 months (Fine et al. 1993). To date, the overall
median survival with GBM with standard therapy is 14.6 months after diagnosis, the 2-year
survival rate is 26.5 % and the 5-year survival rate is 9.8 % (Stupp et al. 2009, Stupp et al.
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2005). With grade II tumors, survival can exceed over 10 years as is the case with grade III
anaplastic oligodendrogliomas. On the other hand, the expected survival of grade III
anaplastic astrocytoma patients is 3.5 years (Stupp et al. 2014). In addition to the short life
estimate, there is also a substantial reduction in QoL.
2.2.7 Animal models of malignant glioma
Ideally, brain tumor models should fulfill the following criteria: they should originate from
glial cells, grow in vitro as  continuous  cell  lines  and  be  capable  of  propagation  by  serial
transplantations in vivo. Tumor growth rates should be predictable and reproducible, and
glioma-like  growth  characteristics  (e.g.  neovascularization,  necrosis  and  invasive  growth)
should be present. The tumors should grow intracranially and their growth kinetics should
be susceptible to therapeutic interventions and to allow monitoring of their efficacy. In the
therapeutic evaluation, tumors should be non- or weakly immunogenic in syngeneic hosts,
and the response to conventional treatments should be predictive of the response in human
tumors (Barth, Kaur 2009, Castro et al. 2011, Candolfi et al. 2007). Although there are
several preclinical models available, none of them fulfills all these criteria (Candolfi et al.
2007, Barth, Kaur 2009).
Most of the models use rodents having tumors either subcutaneously (heterotopically) or
intracranially (orthotopically). Tumors are often introduced by inoculation of a tumor cell
line or transplanting tumor tissue into the target location. Chemicals such as nitrosoureas
have been used as mutagens to create these models (Barth, Kaur 2009, Laerum et al. 1977).
Xenograft models using human MG cells demand an immunocompromised host in order to
avoid immune responses whereas in syngeneic models immunocompetent rodents can be
used (Candolfi et al. 2007). These implantation models often have efficient gliomagenesis,
reproducible growth rates and accurate knowledge of the tumor location, whereas
endogenous spontaneous tumor initiation is lacking. The glioma-like growth characteristics
depend on the model used (Candolfi et al. 2007, Chen et al. 2013). However, the lack of an
intact immune system in xenograft models prevents their use in immunotherapeutic
applications and this should be kept in mind with other applications (Candolfi et al. 2007,
Kroeger et al. 2010). Genetically engineered mouse models obtained with insertion of
oncogenes or knockout of tumor suppressor genes either in germline or somatic cells have
also been applied (Chen et al. 2013, Marumoto et al. 2009). The genetic glioma models are
intended to mimic molecular and histological features of human MGs as well as the
tumorigenic process itself. Their weaknesses are costly, time-consuming and slower tumor
development, and relatively poor prediction of drug therapeutic response (Chen et al.
2013). The only spontaneous GBM model in use is a canine model which displays a
pathogenic resemblance to humans enabling also easier resection of tumors as a large
animal model (Chen et al. 2013). Individual animal models have been reviewed elsewhere
for example by Candolfi et al. (Candolfi et al. 2007) and Barth & Kaur (Barth, Kaur 2009).
2.3 GENE THERAPY
2.3.1 Concepts
Gene therapy can be defined as delivering genetic material into a target cell with a
therapeutic intent. Cancer is nowadays the most common disease being treated by gene
therapy (Figure 3), although originally gene therapy was applied mainly to monogenic
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diseases (Verma, Somia 1997). Gene therapy can either be targeted to somatic cells or germ-
line, latter being transmitted to next generations. Only somatic cell gene therapy has been
permitted up to date (Wirth, Parker & Yla-Herttuala 2013). Foreign genetic material, i.e. a
transgene, can be taken to its target in several ways. When introduced in cell culture, the
term in vitro is used. The introduction of a transgene into a patient can be done directly in
vivo or alternatively ex vivo. When the ex vivo approach is used either autologous or
heterologous cells are transduced outside the patient followed by introducing them into the
patient. In the case of heterologous cells, the recipient’s immune system may become
activated and destroy the cells unless they are protected in some way, for example by
encapsulation. (Verma, Weitzman 2005)
The first FDA approved gene therapy clinical protocol was initiated in 1989. The aim of
this protocol was to track the movements of tumor infiltrating lymphocytes in melanoma
patients after ex vivo gene transfer of the neomycin marker gene (Rosenberg et al. 1990).
One year later, the first human gene therapy with therapeutic intent was conducted. Two
children with a monogenetic immunodeficiency, adenosine deaminase severe combined
immunodeficiency (ADA-SCID), were treated with white blood cells which were ex vivo
transduced with a normal ADA gene. One of the children had a temporary treatment
response, however debatable because of a simultaneous enzyme replacement therapy
(Blaese et al. 1995). Subsequently the number of human gene therapy trials has expanded.
The  first  gene  therapy  product  to  be  approved  was  Gendicine  in  China  in  2003.  This
product contains a recombinant adenovirus-p53 and was approved for the treatment of
head and neck squamous cell carcinoma (HNSCC) (Pearson, Jia & Kandachi 2004, Wilson
2005). (Wirth, Parker & Yla-Herttuala 2013, Wirth et al. 2009)
Figure 3. Indications of gene therapy clinical trials (modified from
http://www.abedia.com/wiley/index.html, updated June 2014)
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2.3.2 Gene therapy vectors
There are different methods that can be exploited to deliver genetic material into a cell;
those can be classified as physical, non-viral and viral. The vehicle used for delivery is
called a vector. Adenoviral vectors are the most commonly used gene delivery vectors
followed by retroviral vectors and plasmids (Figure 4). Each type of vector has its own
advantages and disadvantages, and can be chosen to best meet the demands of the
application. Varying properties include target preferences, efficacy of gene transfer, toxicity
and immune response and duration of the gene transfer. A low gene transfer efficacy is still
one of the major problems associated with limited therapeutic efficacy (Pulkkanen, Yla-
Herttuala 2005). In oncological applications, this is at least partly explained by inability to
reach a  large  number  of  tumor cells  as  well  as  limited vector  spreading within the  tumor
mass (Lawler, Peruzzi & Chiocca 2006). The beneficial properties of gene therapy vector
include high efficiency and specificity in target cells whether dividing or non-dividing,
sufficient duration of expression, easy and cost-effective manufacturing at high
concentrations with no limitations due to insertion capacity and safe re-administrations
without adverse effects or immune response unless this is a desired property (Wirth 2011).
Figure 4. Vectors  used  in  gene  therapy  clinical  trials  (modified  from
http://www.abedia.com/wiley/index.html, updated June 2014)
2.3.2.1 Adenoviral vectors
Adenoviruses  (AVs)  are  DNA viruses  causing mainly  respiratory tract,  eye,  intestine  and
urinary tract membrane infections in humans (Verma, Weitzman 2005). The gene therapy
vectors created based on AV genome are non-pathogenic and most often made replication-
deficient by deletion of E1 and E3 genes. Further removal of viral genes in the second
generation vectors increases the transgene capacity and with the so-called “gutless”, 3rd
generation vectors having all the viral genes removed, the packaging capacity is up to 36 kb
(Alba, Bosch & Chillon 2005). Oncolytic AVs retaining their replicative capability in tumor
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cells have also been used in MG applications (Jiang et al. 2009, Castro et al. 2014). Although
there are over 50 existing serotypes, most vectors used in clinical trials belong to serotypes
2 and 5 (Giacca, Zacchigna 2012). AV vectors do not integrate into the host genome and
have a transient expression. AV vectors can transduce both dividing and non-dividing cells
and they can be produced in high titers up to 1013 particles/ml (Kootstra, Verma 2003). The
side effects of AV gene transfer include the potential immunogenicity, which prevents re-
administration of the same vector (Kafri et al. 1998, Yang et al. 1994). The prevalence rates
of neutralizing antibodies against serotype 5 AVs in some human populations are close to
90 % (Chen et al. 2010). The primary AV receptor, CAR is often down-regulated in several
cancers including MG (Kim et al. 2003). On the other hand, AV vectors in clinical use have
proven to be safe (Hedman et al. 2009, Immonen et al. 2004, Muona et al. 2012). (Lawler,
Peruzzi & Chiocca 2006, Verma, Weitzman 2005)
2.3.2.2 Retroviral and lentiviral vectors
Retroviruses  (RVs)  are  a  large  group  of  RNA  viruses.  They  have  a  common  property  of
reverse transcribing their single stranded-RNA into double stranded-DNA and
subsequently integrating into the host genome to allow long-term expression. Each RV has
a characteristic pattern of integration within the mammalian genome (Cavazza, Moiani &
Mavilio 2013). All RVs have three common genes: gag for the structural proteins, pol for the
viral enzymes and env for the envelope glycoproteins (Singer, Verma 2008). In addition,
more complex viruses have additional regulatory proteins. During the development of
safer vector constructs, most of these regulatory proteins have been removed and the
necessary ones expressed in trans from helper constructs in vector production (Dropulic
2011). The transgene capacity of RV vectors is 8-10 kb and they integrate into host genome
having therefore persistent expression. Traditional RVs infect only dividing cells excluding
lentiviruses (LVs), which can also infect non-dividing cells (Naldini et al. 1996b). Most LV
vectors are based on human immunodeficiency virus-1 (HIV-1) genome, although non-HIV
LVs have been used as well (Valori et al. 2008). The tropism of these viruses is largely
dependent  on  envelope  glycoprotein  and  can  be  modified  to  broaden  the  tropism  and
strengthen the virus for purification process during vector production. The most common
envelope glycoprotein in pseudotyping is the vesicular stomatitis virus glycoprotein (VSV-
G) (Singer, Verma 2008). LV vectors have been shown to efficiently transduce most cell
types in the brain, resulting in long-term transgene expression (Jakobsson, Lundberg 2006,
Naldini et al. 1996a). For example, they have been used in functional genomics applications
such as libraries expressing cDNAs or shRNAs, and animal model applications like
transgenesis (Dropulic 2011, Wiznerowicz, Trono 2005). Unlike AVs, RVs have lower
toxicities and they are less immunogenic. Another advantage is the lack of pre-existing
immunity to vector components in most subjects unlike with AV and adeno-associated
virus (AAV) vectors (Matrai, Chuah & VandenDriessche 2010). However, the potential
disadvantage in their use is the possibility of insertional mutagenesis caused by the vector
integration into a susceptible genomic site causing for example proto-oncogene activation
as will be discussed further in chapter 2.3.4. (Lawler, Peruzzi & Chiocca 2006, Sinn, Sauter
& McCray 2005)
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2.3.2.3 Other viral vectors
Herpes simplex-1 viruses (HSV1) are double-stranded, neurotropic DNA viruses capable of
accommodating large or multiple transgene cassettes when used as gene transfer vectors.
They have a broad host range with a variety of cell types, can infect both dividing and non-
dividing cells, and express transgenes long term via latent neuronal infection. There are
two types of HSV1 based gene transfer vectors: recombinant and amplicon vectors with
both having the safety advantage of deletion of viral replication genes. In addition, there
are oncolytic HSV1 vectors (oHSV1) capable of selective replication in tumor cells based on
the deletion of nonessential gene(s) conferring tumor-restricted replication and lysis.
(Frampton et al. 2005, Gatson, Chiocca & Kaur 2012, Grandi et al. 2009)
AAVs are single-stranded DNA viruses belonging to the family of Parvoviridae. There are
currently 14 known serotypes with varying tissue preferences, AAV-2 being the
predominant one. AAVs need a helper virus, adeno-, herpes-, papilloma- or vaccinia virus,
to facilitate efficient infection and replication. They transduce both dividing and non-
dividing cells but are non-pathogenic to humans. They persist mainly in episomal forms,
but also sometimes in integrative forms resulting in long-term stable expression. The small
capacity for transgenic DNA (<5 kb) and laborious production process are factors limiting
the clinical utility of this transgene vector although AAV has been shown to be safe and to
trigger a very limited immune response. (Buning et al. 2008, Goncalves 2005, Atchison,
Casto & Hammon 1965)
Baculoviruses (BV) are large double-stranded DNA viruses infecting mainly insect cells
and thus are non-pathogenic to humans. The Baculoviridae family  consists  of  about  700
known members Autographa californica multiple nucleopolyhedrovirus (AcMNPV) being
the prototypic baculovirus. As gene transfer vectors, they are easily manipulated with the
possibility of incorporating large inserts (> 38 kb), they can be readily produced and
purified,  and  can  be  transduced  into  most  of  the  cell  types.  Their  safety  features  include
their inability to replicate in mammalian cells as well as their low cytotoxicity. However, in
vivo they are quickly cleared from the circulation by the complement system. (Airenne et al.
2013, Hu 2008)
Some other less commonly used viral gene transfer vectors have been summarized in the
review by Räty et al. (Raty et al. 2008).
2.3.2.4 Non-viral vectors and physical methods
The most commonly used non-viral gene therapy vectors include naked DNA, cationic
lipids, polymers and peptide-based gene delivery systems (Glover, Lipps & Jans 2005,
Schatzlein 2001). These have a safety advantage over viral vectors, less restrictions of
transgene size, cheaper production with better scalability and no risk of insertional
mutagenesis as with integrating viral vectors. However, their transfection efficacy is lower
and their expression is transient (Raty et al. 2008). There are also physical methods of gene
transfer e.g. electroporation, hydrodynamic delivery, ultrasound, microinjection and
ballistic delivery (Glover, Lipps & Jans 2005, Al-Dosari, Knapp & Liu 2005, Hosseinkhani et
al. 2003, Wells 2004).
2.3.3 Gene therapy of malignant glioma
MG is an ideal target for gene therapy due to its local occurrence in spatially restricted
environment in CNS and rarely has a metastasizing character (Pulkkanen, Yla-Herttuala
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2005). The incidence of distant metastases has been shown to be 0.4-0.5 %, bone, lymph
nodes,  lungs  or  liver  being the  target  tissues  (Fonkem,  Lun & Wong 2011,  Pasquier  et  al.
1980). On the other hand, the recent observation by Müller et al. claimed that circulating
tumor cells could be found in peripheral blood of ~20 % of GBM patients (Müller et al.
2014). However, no extracranial metastases or correlation to OS were detected in these
patients, warranting further investigation of their significance.
There is a need for alternative treatment options like gene therapy since there has been
only little progress in the prognosis of MG patients during the last decades. Several
different approaches for MG gene therapy have been evaluated including suicide gene
therapy, anti-angiogenic gene therapy, immunotherapy and oncolytic virotherapy.
2.3.3.1 Suicide gene therapy
Suicide gene therapy is synonymously also called gene-directed enzyme prodrug therapy
(GDEPT), molecular chemotherapy, enzyme-activating prodrug therapy and gene prodrug
activation therapy (Denny 2003, Portsmouth, Hlavaty & Renner 2007). It is a process where
the expression of  an exogenous enzyme catalyses  the  formation of  a  toxic  product  from a
nontoxic  prodrug substrate.  Optimally,  the  suicide  gene should either  be  absent  from the
human genome or expressed at very low levels, exhibit high catalytic activity, be necessary
and sufficient for full prodrug activation, and be easily modified and included into
transgene vectors (Portsmouth, Hlavaty & Renner 2007). The ideal prodrug should have a
high affinity for the suicide enzyme but low affinity for endogenous enzymes, have good
ability to penetrate tumors, and be efficiently taken up by the tumor cells, as well as being
highly toxic only upon activation (Portsmouth, Hlavaty & Renner 2007). Several different
suicide gene prodrug combinations have been described, but none of these fulfills all of
these criteria (Aghi, Hochberg & Breakefield 2000, Denny 2003, Portsmouth, Hlavaty &
Renner 2007).
2.3.3.1.1 Herpes simplex virus-1 thymidine kinase / ganciclovir therapy
Herpes Simplex virus-1 thymidine kinase combined with the prodrug ganciclovir (HSV-
TK/GCV) has been the most extensively studied and well-known suicide gene therapy
system (Portsmouth, Hlavaty & Renner 2007, Aghi, Hochberg & Breakefield 2000). Its
potential for cancer treatment was postulated already in late 1980s (Moolten 1986) and the
first proof-of-concept for its application in vivo in murine sarcomas was demonstrated in
1990 (Moolten, Wells 1990). GCV is a synthetic acyclic analogue of 2’-deoxy-guanosine and
it was originally used as an antiviral drug (Maatta et al. 2009). In cytotoxic gene therapy
(Figure 5),  GCV is phosphorylated to its monophosphate form by HSV-TK and to di- and
tri-phosphates  by  guanylate  kinase  and  further  by  other  cellular  kinases  such  as
phosphoglycerate kinase (Aghi, Hochberg & Breakefield 2000). GCV-triphosphate is a poor
substrate  for  DNA  polymerase  since  it  does  not  possess  a  3’  hydroxyl  group  resulting  in
chain termination and cell death soon after its incorporation into DNA (Ilsley et al. 1995).
HSV-TK/GCV cytotoxicity is cell cycle dependent and for this reason, it is mainly dividing
cells that are affected. This is a benefit in CNS where the tumor is largely surrounded by
non-dividing  brain  parenchyma  cells.  The  exact  mechanism  of  HSV-TK/GCV  cytotoxicity
remains obscure and has been shown to be cell-type dependent (Fillat et al. 2003). The
GCV-triphosphate interaction with DNA results in the appearance of non-functional DNA
fragments inducing apoptosis in cancer cells (Freeman et al. 1993). Cell death is also
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induced by increased accumulation of p53 and death receptors, and finally caspase
activation, resulting in loss of mitochondrial membrane potential and release of cytochrome
c (Beltinger et al. 1999). It has also been speculated that activated antitumoral immune
response against nontransduced cells (Kianmanesh et al. 1997, Vile et al. 1997), and immune
cells infiltration locally and systemically are contributors to HSV-TK/GCV mediated
antitumor effect (Barba et al. 1994, Dewey et al. 1999, Rainov et al. 2000, Immonen et al.
2004). Over the years, the efficacy of HSV-TK/GCV treatment has been improved by
introducing novel splice-corrected (Chalmers et al. 2001) and mutated (Black, Kokoris &
Sabo 2001, Preuss et al. 2011) HSV-TK variants. Their enhanced GCV affinity enables for
less immunosuppressive GCV doses to be used.
The  bystander  effect  is  an  important  phenomenon  further  enhancing  the  efficacy  of
several suicide gene therapies including HSV-TK/GCV. Although observed in early studies
by Moolten et al., Culver et al. 1992 and Freeman et al. 1993 were the first researchers to
report  that  even  low  amounts  of  TK-positive  tumor  cells  could  achieve  tumor  growth
restriction (Culver et al. 1992, Freeman et al. 1993). It has been estimated that only about 10
% of  the  tumor cells  need to  express  HSV-TK gene in  order  to  prevent  the  tumor growth
with GCV administration (Sandmair et al. 2000b, Freeman et al. 1993). Several mechanisms
have been postulated to account for the bystander effect, although the transfer of toxic GCV
metabolites  through  gap  junctions  from  TK-positive  to  TK-negative  cells  leading  to  cell
death is the most widely acknowledged mechanism (Asklund et al. 2003, Touraine et al.
1998). Other mechanisms have been proposed e.g. induction of apoptosis of nontransduced
cells by accumulation of GCV-triphosphates in the surrounding cells (Hamel et al. 1996),
killing of tumor endothelial cells (Ram et al. 1994), and activation of a host immune
response against the tumor cells due to HSV-TK expression and exposure of tumor antigens
after surrounding cell death (Vile et al. 1997). Normal brain cells have been shown to
contribute to the bystander effect without being eliminated by GCV themselves (Miletic et
al. 2007).
Soon after the first proof-of-concept study in 1990, several clinical phase I/II studies
applying HSV-TK producing retroviral packaging cell (RV-VPC) intratumoral injections
combined to systemic GCV for recurrent GBM were conducted (Klatzmann et al. 1998,
Oldfield et al. 1993). However, in phase III multicenter randomized controlled trial (RCT) in
newly diagnosed GBM patients, RV-VPC treatment of HSV/GCV with standard treatment
failed to improve PFS as well as OS (Rainov 2000). In the same year, Sandmair et al.
published a phase I/IIa study where AV HSV-TK/GCV therapy was shown to significantly
increase survival in comparison to RV as well as control group (15 vs 7.4 vs 8.3 months). In
addition, AV vectors were shown to have a higher transduction efficacy and transgene
expression than could be obtained with RV vectors (Sandmair et al. 2000a). AV vectors
were also found to be superior over RV vectors in vivo in MG patients after -galactosidase
gene transfer (Puumalainen et al. 1998). The phase IIb trial, conducted by Immonen et al.,
was the first RCT to achieve increased survival of patients administered sitimagene
ceradenovec  (Cerepro®,  Ark  Therapeutics  Ltd.,  AV  vector  encoding  for  HSV-TK)
compared with patients receiving standard care (Immonen et al. 2004). A significant
increase in survival was maintained even in a separate analysis with GBM patients only
excluding lower grade MGs. Encouraged by these results, a phase III multicenter, standard
care RCT with Cerepro® was conducted in patients with operable primary MGs. When
compared with standard care, Cerepro® was found to prolong the time to re-intervention
19
or death after surgery in GBM patients. However, there was no significant effect on OS.
Although  adverse  effects,  most  commonly  transient  hemiparesis,  hyponatremia  and
seizures, were more common in the treatment group, overall the treatment was considered
to be safe being in line with preclinical safety assessment (Westphal et al. 2013, Langford et
al. 2009). Based on the trial results, European Medicines Agency (EMA) proposed a further
clinical evaluation of Cerepro® to provide sufficient evidence of clinical benefit over
current standard treatment.
Figure 5. Mechanism of HSV-TK/GCV suicide gene therapy. Herpes simplex virus-1 thymidine
kinase (TK) is introduced into target cells via gene transfer with adenoviral vectors. TK
phosphorylates non-toxic prodrug ganciclovir (GCV) into GCV-monophosphate (1P), which is
further  phosphorylated  into  di-  (2P)  and  triphosphate  (3P)  forms  by  cellular  kinases.  In
proliferating cells, GCV-3P is incorporated into DNA resulting in chain termination and apoptosis
of the cell. The cell death is further propagated in nontransduced neighboring cells by GCV-3P
travelling through gap junctions. Modified from Castro et al. 2014.
2.3.3.1.2 Tomato thymidine kinase / azidothymidine therapy
In CNS diseases like MG, the chemotherapeutic agent or a prodrug should be readily able
to penetrate through the BBB in order to reach its target and interact with the intracranially
administered suicide gene (Portsmouth, Hlavaty & Renner 2007). AZT (azidothymidine,
Zidovudine®), an analogue of thymidine and a drug originally used to treat HIV patients,
has been shown to easily penetrate BBB and it has a well-known safety profile obtained
after several years of clinical experience (Denny 2003). Human deoxynucleoside kinases
(dNK)  poorly  phosphorylate  the  parent  compound  into  the  diphosphate  form  (AZT-DP),
presenting a safety advantage while preventing unwanted activation (Lavie et al. 1997). A
thymidine kinase 1 (TK1) –like enzyme from tomato plant (ToTK) has been so far the only
TK1  enzyme  found  to  be  able  to  efficiently  phosphorylate  AZT  into  its  mono-  (AZT-MP)
and diphosphate (AZT-DP) form and the enzyme displays high substrate specificity for
AZT (Khan et al. 2010). ToTK has been shown always to exist in a highly active form,
independent of ATP availability (Khan et al. 2010, Mutahir et al. 2011). The enzymatic
efficiency is at least partly contributed to the inefficient negative feedback regulation of
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thymidine triphosphates (Larsen, Munch-Petersen & Piskur 2014). The ToTK/AZT
combination has shown to be an efficient suicide gene therapy in MG cells and neural stem
cells have been utilized as a suicide gene vehicle in rat MG application (Khan et al. 2010).
2.3.3.2 Anti-angiogenic therapy
In angiogenesis, new capillaries are formed from the pre-existing vasculature and this is
considered  as  one  of  the  hallmarks  of  cancer,  GBM  being  one  of  the  most  angiogenic
cancers (Hanahan, Weinberg 2011, Louis 2006). The importance of tumor angiogenesis was
hypothesized by Dr. Judah Folkman in 1971 (Folkman 1971). In tumor angiogenesis, cells
have to acquire an angiogenic phenotype, turning on a so-called “angiogenic switch” in
order to be able to maintain their supply of nutrients and oxygen (Hanahan, Folkman 1996).
The balance between pro- and anti-angiogenic factors is important and those factors can be
targeted in therapeutic applications, for example with neutralizing antibodies and receptor
tyrosine kinase inhibitors (RTKIs). Anti-angiogenesis can be introduced either by down-
regulating the proangiogenic factors like vascular endothelial growth factor A (VEGF-A)
(Ellis, Hicklin 2008, Ferrara 2002), fibroblast growth factor (FGF) or platelet-dericed growth
factor (PDGF), or via the upregulation of anti-angiogenic factors like thrombospondin-1
(TSP-1), angiostatin or endostatin (Carmeliet, Jain 2000, Samaranayake et al. 2010). So far,
the only clinically approved anti-angiogenic agent is Bevacizumab, which is discussed
briefly in the “Targeted therapies” section 2.2.5.4.1 (Tabatabai, Stupp 2009).
The effects of anti-angiogenic therapies are partly mediated by vascular normalization in
which peri-tumoral vasogenic edema is reduced, therefore alleviating adverse symptoms
and improving QoL (Batchelor et al. 2007, Jain 2005). Vascular normalization has also been
thought  to  temporarily  improve  chemotherapy  penetration  into  the  tumor  bed  as  well  as
enhancing the intratumoral distribution of the injected viral vectors (Jain et al. 2007, Gatson,
Chiocca & Kaur 2012). Resistance to antiangiogenic therapies may develop through the
activation of compensatory angiogenic mechanisms, protection of the tumor vasculature by
proangiogenic inflammatory cells and increased pericyte coverage and enhanced tumor
invasiveness, vessel co-option and metastasis (Bergers, Hanahan 2008, Samaranayake et al.
2010).
2.3.3.3 Immunotherapy
The brain was long considered a niche where the immune system had only a limited
detection and elimination capacity towards foreign antigens, a state referred to as “immune
privilege”. This was thought to be due to the low number of dendritic cells in the brain, the
lack of lymphatic drainage and the production of anti-inflammatory mediators (Assi et al.
2012, Lowenstein et al. 2007). However, recently there has been increasing evidence of CNS
immunocompetence and active interactions with the peripheral immune system, and
therefore an increase in the interest of developing immunotherapy for GBM (Jackson, Lim
& Drake 2014, Reardon et al. 2013, Reardon et al. 2014). The most extensively studied and
well-established immunotherapy for GBM has been vaccination either with tumor lysate or
synthetic tumor antigens (Jackson, Lim & Drake 2014, Reardon et al. 2014). In vaccination,
target specific antigen(s) along with an immunostimulatory adjuvant is taken up by antigen
presenting cells (APC), most often ex vivo propagated dendritic cells, and presented in
antigen-MHC (major histocompatibility complex) to elicit a T-cell response in the patient.
Several glioma-associated antigens have been recognized and immunotherapy trials are
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ongoing, with EGFRvIII vaccine strategies being the most extensively studied (Jackson, Lim
& Drake 2014, Reardon et al. 2013). Vaccination strategies can further be enhanced by
adopting other immunomodulatory approaches, for example AV TK/GCV + Flt3L (fms-like
tyrosine kinase 3 ligand) gene therapy (Mineharu et al. 2011). The T-cell response can also
be elicited by directly introducing immune mediators such as interferons or interleukins
into the patient for example by using gene transfer vectors (Castro et al. 2011). Some other
immunotherapy strategies include immune checkpoint inhibitors, like CTLA-4 (Cytotoxic T
lymphocyte antigen-4) blocking antibodies enabling immunological elimination of tumor
cells (Hodi et al. 2010), and a reduction in the number or activity of immunosuppressive
regulatory T cells (Curtin et al. 2008).
2.3.3.4 RNA interference
RNA interference (RNAi), a universal mechanism of gene silencing, was first discovered in
C. elegans by Fire et al. in 1998 (Fire et al. 1998) and a few years later found to be functional
also in mammalian cells (Elbashir et al. 2001). The mediators of RNAi are approximately 20-
30 nucleotides (nt) long RNA molecules, either exogenously transfected small interfering
RNAs (siRNAs) or small hairpin RNAs (shRNAs) encoded by gene transfer vectors within
the  cell  (Dykxhoorn,  Novina  &  Sharp  2003).  ShRNAs  are  transcribed  within  the  nucleus,
exported to cytoplasm by Exportin-5 and processed by the Dicer complex into ~21-25 nt
siRNA fragments. These siRNAs, either processed from shRNA or exogenously introduced,
are  loaded  into  RISC  (RNA-induced  silencing  complex)  where  the  guide  RNA  strand
mediates either a direct sequence specific cleavage or translational repression and RNA
degradation. The former is induced by full complementarity of the siRNA with the mRNA
target sequence, whereas the latter is a result of partial complementarity. In addition to
these post-transcriptional gene silencing (PTGS) mechanisms, promoter-complementary
siRNAs  can  mediate  transcriptional  gene  silencing  (TGS)  in  nucleus  triggering  chromatin
remodeling and histone modifications (Castanotto, Rossi 2009) (Figure 6).
Several RNAi based applications have been developed (Castanotto, Rossi 2009, Dillon et
al. 2005) and the first human clinical trial started in 2004 for the wet age-related macular
degeneration (Whelan 2005). In MG, impaired tumor growth has been achieved for
example in murine models after RNAi against hypoxia inducible factor-1 (HIF-1)
(Gillespie et al. 2007), Src (Gillespie et al. 2007, Stedt et al. 2012) and Mgmt combined with
TMZ (Viel et al. 2013). RNAi against Tenascin-C (TN-C), an extracellular matrix protein, has
been claimed to improve OS of patients with MG (Rolle et al. 2010). However, RNAi based
therapeutics have also raised some safety concerns, namely induction of specific side effects
through partial sequence complementarity and unspecific side effects like triggering an
interferon response (Bridge et al. 2003). In addition, siRNA-mediated saturation of the
above described cellular machinery processing also microRNAs (miRNAs) may cause
perturbations in essential cellular functions (Grimm et al. 2006, Khan et al. 2009).
MiRNAs are a group of endogenous non-coding RNAs (ncRNAs) regulating various
cellular processes through the mechanisms described above (Visone, Croce 2009,
Castanotto, Rossi 2009). Deregulation of miRNAs has been linked to initiation, progression
and metastasis of many cancers including MG (Hermansen, Kristensen 2013, Palumbo et al.
2014). Several miRNAs have been shown to be either upregulated or downregulated in MG,
although some of the findings are somewhat contradictory. The potential of miRNAs as
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cancer biomarkers and treatment options as well as their roles in predicting treatment
response and survival is only beginning to be elucidated (Hermansen, Kristensen 2013).
Figure 6. Mechanism of RNA interference. a, Primary microRNAs (pri-miRNAs) are processed to
precursor  miRNAs  (pre-miRNAs)  by  the  Drosha  complex  and  transported  to  cytoplasm  by
Exportin 5 (XPO5). b, Similarly artificially transcribed shRNAs, either from plasmid or other
vectors, are transported to cytoplasm by XPO5. In the cytoplasm, these double stranded RNAs
(dsRNAs)  are  processed  by  Dicer  containing  the  pre-RISC  complex  and  the  processed  guide
strand in RISC (RNA-induced silencing complex) transports the complex to complementary
mRNA  sequence.  With  full  complementarity  (left  pathway),  the  target  mRNA  sequence  is
degraded through Argonaute 2 (AGO2)-mediated cleavage. With partial complementarity (right
pathway), translational inhibition occurs accompanied by non-sequence-specific degradation of
mRNA in P bodies. c, In addition, transcriptional gene silencing via chromatin remodeling and
histone modifications can occur in the nucleus with promoter-complementary siRNAs. Modified
from Castanotto et al. 2009.
2.3.3.4.1 Src
Src is a nonreceptor tyrosine kinase belonging to a family of Src family kinases (SFKs) with
eight other members (Summy, Gallick 2006). It is located downstream of several growth
factor receptors (receptor tyrosine kinases) and it functions by phosphorylating specific
tyrosine residues in other proteins (Alvarez, Kantarjian & Cortes 2006). Src was the first
tyrosine kinase to be characterized in 1979 (Oppermann et al. 1979) and since then it has
been shown to be a central mediator of various physiological and pathological processes
such as proliferation, migration, angiogenesis, invasion and survival via various signaling
pathways (Ahluwalia et al. 2010) some of which are illustrated in Figure 7. These processes
are also considered to be necessary for tumourigenesis, and therefore the role of Src has
been studied in detail in various cancers including MG (Alvarez, Kantarjian & Cortes 2006,
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de Groot, Milano 2009). Transgenic mice expressing v-Src (viral homologue of cellular Src)
develop glioblastoma tumors closely resembling human tumors, evidence for a role for Src
in glioma development and progression (Weissenberger et al. 1997). Src activity has been
shown to be elevated in human GBM likely due to increased activation of cell surface
growth factor receptors and integrins since no gene amplification or mutations have been
detected in GBM tumors (Cancer Genome Atlas Research Network 2008).
Figure 7. Signaling network of Src-mediated tumor progression. Interaction of Src with receptor
tyrosine  kinases  (RTK),  integrins  and  focal  adhesion  kinase  (FAK)  activates  the  Src  kinase
activity and further downstream signaling resulting in cellular responses like angiogenesis,
survival, proliferation and motility/migration/invasion. Some of the signaling intermediates in
the corresponding pathways are shown. However, not all signaling pathways are well
characterized with unknown mediators and connections. In addition there is considerable
“crosstalk”  in  the  illustrated  pathways  not  demonstrated  by  arrows.  For  more  details  of
individual signaling molecules, please refer to the original publications. Modified from Ahluwalia
et al. 2010 and Summy & Gallick 2006.
Src deficient (src-/-) mouse models have exhibited reduced tumor-induced vascular
permeability, resulting in anti-invasive and anti-metastatic properties (Criscuoli, Nguyen &
Eliceiri 2005, Lund et al. 2006, Weis et al. 2004), and therefore Src inhibitors have been
proposed to be combined with treatments aimed at reducing the tumor bulk itself (Brunton,
Frame 2008). Different therapeutic agents capable of inhibiting SFKs in MG have been
studied including small molecule inhibitors like Dasatinib, PP2 and SU6656 (Araujo,
Logothetis 2010, Zhang, Yu 2012, Ahluwalia et al. 2010) as well as shRNAs (Stedt et al.
2012). None of the SFK inhibitors in clinical testing (Dasatinib, Saracatinib, Bosutinib) have
received approval from FDA for the treatment of solid tumors because the results have not
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been encouraging. Dasatinib (SFK/ABL dual inhibitor) has been clinically assessed for GBM
therapy both as a monotherapy and in treatment combinations. It has received FDA-
approval for the treatment of chronic myeloid leukemia and Philadelphia chromosome-
positive acute lymphoblastic leukemia (Zhang, Yu 2012). In addition to combination
treatments, the discovery of effective response biomarkers and pre-selection of patients
based  on  these  markers  have  been  suggested  to  improve  the  success  of  SFK  inhibitors
(Zhang, Yu 2012).
2.3.3.5 Other gene therapy strategies
In addition to the above strategies, there are several other gene therapy options available
including  targeted  toxins,  oncogene  and  tumor  suppressor  gene  therapy,  and  oncolytic
virotherapy, examples of which are given below.
Targeted toxins are formed from two components: a ligand of the targeted receptor
exclusively overexpressed on the target cells and a radioisotope or a toxin moiety consisting
of catalytic and translocation domains of highly toxic bacterial products such as
Pseudomonas or Diphteria exotoxin. Once the ligand-toxin fusion has been selectively
internalized into the target cell, the toxin inhibits protein synthesis triggering cell death
(Castro et al. 2011). An example of a ligand-receptor couple is interleukin-13 (IL-13) and its
receptor IL-13R2 overexpressed on glioma cells. IL-13 has been fused to mutated
Pseudomonas exotoxin to create IL-13 toxin, which has been further improved and shown to
possess both high safety and efficacy in murine in vivo GBM applications (Candolfi et al.
2010).
Mutations in oncogenes and tumor suppressor genes create the basis for a multistep
process of cancer development. These pathways have been partly discussed in
“Pathogenesis and molecular biology” section 2.2.3. Mutations in tumor suppressor p53 are
the most common alterations seen in 25-30 % of primary and 60-70 % of secondary GBMs
(England, Huang & Karsy 2013). Therapeutic approaches aiming at replacing mutant p53
by gene transfer of wild-type p53 or reactivation of wild-type p53 have been investigated.
The AV gene delivery of p53 was evaluated in a phase I clinical trial of MG which
demonstrated the safe expression of functional protein, however, within a limited distance
from the injection site (Lang et al. 2003). Although inactivation of p53 occurs early in
gliomagenesis (Castro et al. 2011), its role as a molecular marker remains controversial since
most studies have failed to show any association with prognosis (England, Huang & Karsy
2013).
Oncolytic virotherapy is based on the concept in which a replicationcapable virus
selectively replicates within tumor cells resulting in cell lysis and further propagation of
viral progeny into the nearby tumor cells. Tumor selectivity can be achieved for example by
retargeting towards tumor-associated receptors like EGFRvIII (Wollmann, Ozduman & van
den Pol 2012). Several oncolytic viruses have been examined in GBM, and at least HSV, AV,
Newcastle disease virus, reovirus, parvovirus, measles virus and poliovirus have advanced
to clinical trials (Wollmann, Ozduman & van den Pol 2012). HSV-based oncolytic viruses
were the first (Martuza et al. 1991) and the most extensively studied oncolytic viruses. The
AV-based oncolytic virus, ONYX-015, demonstrated good safety in a phase I clinical trial of
MG, although it was concluded that potential for efficacy warranted further investigation
(Chiocca et al. 2004). In 2005, China approved an almost identical AV-based therapy for
HNSSC as the world’s first oncolytic virus therapy for cancer (Garber 2006).
25
2.3.4 Safety and ethics
Over the years,  continuous efforts have been made to enhance the safety of gene therapy.
Safety aspects in vector development are reflected in the different generations of gene
transfer vectors. In AV vectors, deletion of replication genes E1 and E3 created the first
generation vectors whereas in third generation “gutless” vectors, all of the viral genes have
been removed. A similar safety evolution has been achieved in LV progressing up to third
generation self-inactivating vectors from which all unnecessary accessory genes have been
removed. For the production purposes, necessary genes, including a transgene, are coded
by separate plasmids further reducing the likelihood of generating replication competent
viruses, the major safety concern. Despite the large-scale production and testing of LVs, no
replication competent viruses have been detected (Cornetta et al. 2011, Manilla et al. 2005).
Other examples of ensuring safety include self-inactivating (SIN)-vectors, optimization of
vector purification and vector administration locally, if possible, to avoid systemic side
effects. (Raty et al. 2008)
Concerns have been raised regarding some properties connected to gene transfer vectors,
namely the risk of an insertional oncogenesis with RV vectors and the possibility for
immune responses mainly with AV vectors. In 1999, a patient suffering from a partial
ornithine transcarbamylase (OTC) deficiency died during a phase I clinical trial aiming at
treating OTC-deficiency with a high dose AV gene transfer. The suspected cause of the
patient’s death was an AV vector-related immune response manifested as acute respiratory
system collapse and subsequent multiorgan failure (Fox 2000, Lehrman 1999). Initially,
innate immune system is activated and after repeated exposures, the adaptive immune
response neutralizes the vector and eliminates transduced cells, possibly preventing the use
of the same vector again. However, in the case of AV vectors, prevalent antibodies from
previous exposure to wild type AVs, are detectable in 97 % of individuals (Chirmule et al.
1999). On the other hand, in diseases like MG, immune activation might also serve as an
enhancer of the treatment response and therefore it could be considered as a beneficial
response (Immonen et al. 2004, Sandmair et al. 2000b).
In the early years of this century, four patients with severe combined immunodeficiency
(SCID-X1) participated in gene therapy trials transferring the missing interleukin 2 receptor
gamma (ILR2G) gene into CD34+ bone marrow precursor cells. These patients developed
leukemias after a few years delay subsequent to the gene therapy and the cause was
considered to be genomic integration of the RV vector used in the trials predisposing the
subjects to leukemia through insertional mutagenesis activated proto-oncogenes (Hacein-
Bey-Abina et al. 2008, Hacein-Bey-Abina et al. 2003). This risk has mainly been associated
with the use of gamma RV vectors (Modlich, Baum 2009, Montini et al. 2006) although its
existence is acknowledged also with LV vectors (Cavazzana-Calvo et al. 2010). As a
solution to insertional oncogenesis, chromatin insulators isolating the viral promoter,
directed integration to a predetermined genomic site and integrase-defective LV vectors
have been proposed (Vargas et al. 2004, Yi, Hahm & Lee 2005, Schenkwein et al. 2013).
However, problems such as random integration can still occur (Tan et al. 2006).
These single, but tragic deaths connected to gene therapy have raised several questions
about safety and ethics of gene therapy in general. On the other hand, in three RCTs of
cardiovascular diseases and MG, the incidences of serious adverse events in AV-treated
patients were 0.9 and 4.0 per 10 000 patient days in cardiovascular diseases and MG trials
as compared to 0.5 and 2.1 in the randomized control patients, respectively (Wirth et al.
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2006). It has to be remembered that the current treatments for MG, i.e. radiotherapy and
chemotherapy, also are subject to severe adverse effects.
The procedure of obtaining approval for a clinical trial in the European Union (EU) is
standardized and includes the completion of an IMPD (Investigational Medicinal Product
Dossier) which contains basic data about clinical study, clinical objectives, vector
description, manufacturing, supply and import, preclinical data and risk assessment, and
information about patients as well as a mandatory informed consent. The IMPD is
evaluated by national agencies as well as the ethical committee, and Good Laboratory
Practices  (GLP),  Good  Manufacturing  Practices  (GMP)  and  if  approved,  Good  Clinical
Practices (GCP) are presumed to be followed (Gonin et al. 2005). These gene therapy related
activities are regulated at the EU level by the Bioethics Directive and Clinical Trials
Directive, as well as being subject to national legislation, such as Gene Technology Law and
Medicines Act in Finland.
Ethical issues concerning gene therapy are vast and complex, and are often loaded with
emotional charge in dialogue. What kind of gene therapy is acceptable, what is the price
and to whom should it be available? Should the applications be limited to defined medical
conditions  or  could  human  traits  also  be  altered?  Nevertheless,  the  active  discussion  and
open interaction between investigators, regulatory authorities and the general public needs
to be maintained.
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3 Aims of the study
MG  is  a  cancer  with  a  poor  prognosis.  There  is  a  clear  need  for  development  of  new
therapeutic strategies to treat these patients. MG is well suited for gene therapy due to its
local occurrence in an anatomically restricted location and non-metastasizing character.
Therefore, the aims were to investigate and evaluate different therapeutic options and their
combinations in vitro and in vivo in preclinical MG models to better understand and further
develop new and current treatment modalities.
The specific aims for this thesis were as follows:
I To study whether it is possible to inhibit tumor cell growth with shRNAs
targeting Src kinase and to translate these in vitro findings into in vivo inhibition
of tumor growth in two separate MG models
II To assess whether VPA could enhance the treatment efficacy of HSV-
TK/GCV+TMZ combination and to further optimize the efficacy of the latter
combination
III To  compare  the  efficacy  of  HSV-TK/GCV  therapy  with  a  novel  suicide  gene
therapy of ToTK/AZT in vitro and in vivo
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4 Materials and methods
The materials and methods used in this study are briefly summarized in the following
tables 3-7. More information about materials and detailed description of the methods can be
found in the original publications (I-III) referred to in the tables. The statistical analyses
used are listed in the original publications.
Table 3. Methods used in original publications I-III
Method Description Original publication
In vitro
DNA cloning Construction of Ad.ToTK vector III
Lentiviral production
Calcium phosphate transfection, viral concentration by
ultracentrifugation and titer determination with FACS and
p24 assay
I
Adenoviral production
Calcium phosphate transfection, plaque selections, viral
concentration by ultracentrifugation and titer
determination by spectrophotometric analysis
II, III
Cell culture
Isolation of human umbilical vein endothelial cells
Cell line and primary cell culture
I
I, II, III
Microscopy
Light microscopy
Fluorescence microscopy
I, II, III
I, II
FACS Transduction efficiency measurement I, II, III
Cell viability
CellTiter-Glo luminescent cell viability assay, CellTiter 96
AQueous One Solution Cell Proliferation Assay
I, II, III
In vitro angiogenesis Tubulogenesis assessment on Matrigel I
Kinase activity assay Radiolabel enzymatic activity measurement III
Methods to study
gene expression
RNA isolation and concentration measurement,
quantitative real-time polymerase chain reaction (qPCR)
I
Methods to study
protein expression
Total protein extraction and concentration measurement
by BCA assay, western blot
Immunohistochemistry (paraffin or frozen sections)
I
I, II, III
Ex vivo / In vivo
Tumor cell inoculation
Subcutaneous (s.c.)
Intracranial (i.c.)
I
I, II, III
Gene transfer Intracranial (i.c.) I, II, III
Manual tumor
measurement 3-dimensional tumor measurement and volume analysis I
MRI, Matlab Tumor confirmation or follow-up, tumor volume analysis I, II, III
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Blood sampling
Full blood counts, clinical chemistry parameters, VPA
concentration measurements
I, II, III
Medication Treatment medications to rodents i.p. / p.o. / s.c. I, II, III
Ad.ToTK, Adenoviral vector including tomato thymidine kinase insert; FACS, Fluorescence-activated cell
sorting; MRI, Magnetic resonance imaging; VPA, Valproic acid; i.c., intracranial; i.p., intraperitoneal; p.o.,
per oral; s.c., subcutaneous.
Table 4. Cell lines and rodent strains
Cell line Description Source Original publication
HUVEC Human umbilical vein
endothelial cells
Isolated from umbilical cords
obtained from maternity
ward of Kuopio university
hospital
I
BT4C Rat glioma cells
Laerum et al. (Laerum et al.
1977)
I, II, III
GL261 Mouse glioma cells
A kind gift from Prof.
Hinkkanen
III
U118MG Human glioma cells ATCC: HTB-15 I, III
U87MG-Fluc
Human glioma cells
expressing luciferase
A kind gift from Prof.
Hinkkanen
III
Rodent strain Description Producer Original publication
NMRI Nude mice Taconic, Ejby, Denmark I
Hsd:AthymicNude-
Foxn1nu Nude mice
Harlan Laboratories, Horst,
Netherlands III
BDIX Immunocompetent rats
Charles River Laboratories,
Lille, France I, II
ATCC, American type culture collection.
Table 5. Viral vectors
Viral vector Description Original publication
LV.shSRC1 Lentiviral vector, Src shRNA insert 1 I
LV.shSRC2 Lentiviral vector, Src shRNA insert 2 I
LV.shGL3 Lentiviral vector, Luciferase shRNA insert I
Ad.GFP
Adenoviral vector, Green fluorescent protein
marker gene insert
II
Ad.LacZ Adenoviral vector, LacZ marker gene insert II
Ad.HSV-TK
(Cerepro®)
Adenoviral vector, Herpes simplex virus-1
thymidine kinase insert
II, III
Ad.ToTK Adenoviral vector, Tomato thymidine kinase insert III
Ad.control Adenoviral vector, no insert III
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Table 6. Pharmaceutical products
Product Description Original publications
AZT Azidothymidine III
DMSO Dimethyl sulfoxide (TMZ dilutions) I, II
dThd Deoxythymidine III
GCV Ganciclovir hydrochloride (Cymevene®) II, III
rEGF Recombinant Epidermal Growth Factor protein I
rVEGF-A
Recombinant Vascular Endothelial Growth Factor
protein I
TMZ Temozolomide (Temodal®) I, II
VPA Valproic acid sodium salt (Deprakine®) I, II
Isoflurane Inhalation anesthetic with N2O/O2 carrier I, II, III
Ketamine Ketalar®, injection anesthetic I, II, III
Medetomidine Domitor®, injection anesthetic I, II, III
Atipamezole Antisedan®, antisedative I, II, III
Carprofen Rimadyl®, analgesic I, II, III
Oftagel Moisturizing eye drops I, II, III
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Table 7. qPCR assays and antibodies
Product Description, Source Original publications
Hs00178494_m1 qPCR assay for human Src, Applied Biosystems I
4333764F qPCR assay for human GAPDH, Applied Biosystems I
-actin Primary ab, Abcam (#ab8227) I
CD34 Primary ab, HyCult Biotechnology (#HM1015) I
Ki-67 Primary ab, Dako (#M7240) I
LYVE-1 Primary ab, ReliaTech (#103-PA50AG) I
MMP-2 Primary ab, R&D Systems Inc. I
Muscle actin Primary ab, Enzo Life Sciences (#ENZ-C34931) I
MxA Primary ab, A kind gift from Prof. Julkunen I
Src Primary ab, Cell Signalling Technology (#2108) I
Goat anti-mouse IgG-
HRP
Secondary ab, Thermo Fisher Scientific (#PI-
31430)
I
Goat anti-rabbit IgG-
HRP
Secondary ab, Thermo Fisher Scientific (#PI-
31460)
I
Connexin 43 Primary ab, Sigma Aldrich (#C6219) II
Biotinylated goat
anti-rabbit
Secondary ab, Vector Laboratories (#BA-1000) II
F4/80 Primary ab, AbD Serotec (#MCA497R) III
Biotinylated rabbit
anti-rat
Secondary ab, Vector Laboratories (#BA-4000) III
ab, antibody; GAPDH, Glyceraldehyde 3-phosphate dehydrogenase; HRP, Horseradish peroxidase; MMP-2,
Matrix metalloproteinase 2
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5 Results and Discussion
In  the  following  sections,  the  results  of  each  study  (I-III)  will  be  briefly  summarized  and
some of them illustrated by figures followed by discussion. More detailed results and
further discussion are provided in the corresponding original publications.
5.1 SRC INHIBITION IN MG (I)
5.1.1 Src shRNAs mediate efficient inhibition in vitro
The  central  role  of  Src  in  tumorigenesis  has  been  acknowledged  in  studies  using  Src-
deficient mice as well as its pharmacological inhibitors (Criscuoli, Nguyen & Eliceiri 2005,
Lund et al. 2006, Weis et al. 2004). It was decided to study the role of specific Src inhibition
on MG growth and the potential of this inhibition as a therapeutic approach. Local tumor
delivery was used to  avoid systemic  side  effects  and to  evaluate  the  responses  within the
tumor tissue. GBM is one of the most angiogenic cancers and Src is important not only for
the tumor cells but also in the endothelial cells lining the vessels (Hanahan, Weinberg 2011,
Werdich, Penn 2005). Therefore, preliminary in vitro testing was conducted in HUVECs.
The LV delivery of shRNAs against Src was shown to inhibit the corresponding mRNA and
protein levels up to 90 % in comparison to nontransduced cells (Figure 8). The functionality
was further proven by inhibition of downstream signaling demonstrated by reduced MMP-
2 known to be important for Src-mediated invasion and metastasis (I). Src inhibition was
also shown to decrease VEGF-A-mediated cell viability as well as to reduce tubulogenesis
mimicking angiogenesis in vitro (I). Altogether, the Src shRNAs used in this study exhibited
high efficacy in several in vitro measurements.
Figure 8. Functionality of shRNAs in vitro.  (a)  The  extent  of  Src  inhibition  in  HUVECs  was
measured  at  the  mRNA  level  by  quantitative  real-time  RT-PCR.  Target  gene  expression  was
normalized to GAPDH mRNA expression. **P<0.01 vs. nontransduced cells. (b) Inhibitory
effects of shRNAs against Src kinase were analysed also on protein level by Western blotting. -
actin was used as a control for sample loading. Quantifications of the Western blots are shown
below each lane. NT, nontransduced; Ctrl, transduced with a control vector expressing shRNA
against  luciferase;  sh1,  shRNA  sequence  1  against  Src;  sh2,  shRNA  sequence  2  against  Src.
Error bars = SEM.
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5.1.2 Effect of transduction efficiency on in vivo tumor growth and survival
The preliminary in vivo efficacy assessment of Src shRNAs was conducted in nude mice in
subcutaneous tumor xenografts to allow convenient follow-up. Those tumors having only
10 % or even 50 % of cells ex vivo transduced with Src shRNAs did not show reduced
growth whereas tumors with almost 100 % of the cells being transduced exhibited a
marked growth reduction, being almost 50-times smaller than the control vector-
transduced  tumors  (Figure  9a).  The  maintenance  of  transduction  over  6  weeks  follow-up
was confirmed post-sacrifice (I). The tumors having ~100 % cells transduced with Src
shRNAs demonstrated reduced Src protein levels (I) and fewer capillaries (Figure 9b),
whereas the proliferation indexes were not significantly different (I).
Figure 9. Functionality of shRNAs in vivo in mouse subcutaneous and rat intracranial glioma
models. (a) Tumor growth was measured during a 6 week follow-up period in nude mice glioma
xenografts.  U118MG  glioma  cells  were  transduced  with  lentiviral  vectors  encoding  shRNAs
against Src and luciferase as a control. Different proportions of transduced cells were implanted
subcutaneously into the flanks of nude mice and tumor growth was measured weekly. The
insert shows tumor growth of sh1 100 % and sh2 100 % groups over the same follow-up period
with  a  more  detailed  scale  on  y  axis.  P<0.05  Ctrl  versus  sh1/sh2  100  %.  (b)  CD34  capillary
immunostaining from mouse tumors, 200x magnification with 100 μm scale. (c) Rat intracranial
MG ex vivo tumor volumes measured by MRI at post-inoculation follow-up. **P<0.01,
***P<0.001 versus nontransduced tumors, #P<0.05 versus control vector-transduced tumors.
ND  =  not  detected  (no  survivors  remaining).  (d)  Rat  MG  survival  proportions  in  days  after
tumor inoculation, ***P<Src sh1_ex vivo versus nontransduced. Ctrl, transduced with a control
vector expressing shRNA against luciferase; NT, nontransduced; sh1/sh2, shRNA sequence 1 or
2 against Src. Error bars = SEM.
The efficacy of Src shRNA1 construct was further studied in a rat orthotopic MG model. Ex
vivo Src  shRNA1  transduced  tumors  were  significantly  smaller  than  nontransduced  or
control vector-transduced tumors conferring a survival benefit on these rats (Figure 9c-d).
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However, with in vivo gene transfers, there were no differences between Src-inhibited
versus controls in either tumor volumes or survival (I). In vivo treatment with Src shRNA1
was further  combined with two drugs  already in  clinical  use,  VPA and TMZ,  to  improve
the treatment efficacy. This combination could reduce the tumor volume to 59 % of Src
shRNA1 tumors only (I). However, the differences in tumor volumes or survival of rats
with the combination treatment were not statistically significant (I).
Src inhibitors have displayed contradictory findings in terms of proliferation inhibition, but
have been claimed to be beneficial in inhibition of invasion and metastasis (Brunton, Frame
2008, Criscuoli, Nguyen & Eliceiri 2005, Lund et al. 2006). Since Src is located in the
immediate vicinity of several growth factor receptors, it has a wide and complex
downstream signaling network (Figure 7). Therefore, its inhibition is likely to affect several
cellular responses; this may be an advantage if one wishes to restrict a broad spectrum of
cellular actions as often is the case in cancer treatment. However, the same broad inhibition
can cause systemic side effects as well as creating a selection pressure towards other
signaling pathways (Rich, Bigner 2004, Sathornsumetee et al. 2007).
The importance of transduction efficiency for therapeutic success was proposed already
several years ago (Pulkkanen, Yla-Herttuala 2005) and is still one of the major challenges of
gene therapy. In the present study, Src shRNAs demonstrated efficient in vitro inhibition as
well  as  marked tumor growth restriction in  nude mice  only  when almost  100  % of  tumor
cells  had  been  transduced.  Based  on  the  results,  it  can  be  concluded  that  level  of  Src
inhibition needs to reach over 50 % for sustained growth inhibition.
Another interesting aspect is the role of immune response for the treatment response.
Tumors  in  nude  mice  retained  their  high  GFP  positivity  as  a  mark  of  high  transduction
efficiency throughout the follow-up. However, in the immunocompetent rats used in the
intracranial MG model, the GFP-positivity of ex vivo transduced tumor cells had decreased
from ~94 % down to 9.7 % in 20 days. In vivo gene transfer efficacy was 6.0 % at 5 days post-
transduction.  Similar  to  the  results  obtained  in  the  nude  mice  experiment,  it  is  therefore
unlikely that these transduction efficiencies could achieve a significant treatment response
with a single gene therapy treatment. There could be several reasons for decreased
transduction efficiency but these remained outwith the scope of this study. However, one
possible explanation is the activity of the immune system towards the gene therapy vector.
Although LV is known to be weakly immunogenic, the construct includes green fluorescent
protein (GFP) known to cause immune reactions (Stripecke et al. 1999). In addition, the role
of an activated interferon response cannot be ruled out based on a single target, namely
MxA, analysis. Another explanation for the overgrowth of nontransduced cells could be the
saturation  of  cellular  RNAi  machinery  in  transduced  cells  processing  both  miRNAs  and
vector-delivered shRNAs (Khan et al. 2009).
Src inhibitors have been suggested for combination therapies (Brunton, Frame 2008). In
this study, a trend towards a beneficial treatment response was detected on tumor volumes
with combination of Src shRNA and TMZ + VPA, however this was not statistically
significant. This further emphasizes the importance of careful optimization of each
individual treatment and their combinations for a maximal treatment response.
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5.2 HSV-TK/GCV+TMZ+VPA COMBINATION TREATMENT FOR MG (II)
5.2.1 VPA enhances HSV-TK/GCV+TMZ treatment in vitro
VPA has a long history as an anticonvulsant and mood-stabilizer, but more recently it has
been utilized for gene therapy as a HDI (Bolden, Peart & Johnstone 2006, Chateauvieux et
al. 2010). VPA has been shown to enhance transduction efficiency and upregulate transgene
expression (Fan et al. 2005, Segura-Pacheco et al. 2007) as well as sensitizing MG cells to
chemotherapeutic agents like TMZ (Ryu et al. 2012). It was therefore combined with
already clinically evaluated HSV-TK/GCV gene therapy and the first-line MG
chemotherapeutic, TMZ. This present study investigated whether VPA could enhance the
treatment efficacy of TK+GCV+TMZ combination and further optimize this combination
therapy. VPA was shown to enhance the cytotoxicity of TK+GCV and TMZ both alone and
in combination in a dose-dependent manner (Figure 10a). It enhanced AV transduction
efficiency (Figure 10b), relocated Cx43 protein to cell junctions (II) and enhanced the
bystander effect (II).
Figure 10. Effect of VPA on glioma cell viability and adenoviral transduction efficiency. (a) Cell
viability of ganciclovir-, temozolomide- and/or valproate-treated BT4C cells was measured using
the MTS assay in Ad.HSV-TK MOI 5 transduced cells. Significances are shown compared with
the GCV-TMZ- group. (b) Transduction efficacy (percentage of GFP-positive cells) measured by
FACS. BT4C cells were transduced with MOI 1 or 5 and treated with increasing concentrations of
VPA.  Significances  are  given  compared  with  no  VPA  with  corresponding  MOI.  GFP,  green
fluorescent protein; MOI,  multiplicity of  infection; GCV, ganciclovir;  TMZ, temozolomide; VPA,
sodium valproate; ±, administered/not administered; *P<0.05 and ***P<0.001. Error bars =
SEM.
5.2.2 No additional treatment benefit with VPA on HSV-TK/GCV+TMZ in vivo
For in vivo testing,  route  of  delivery  and  dosing  of  VPA  were  optimized  ending  up  with
subcutaneous dosage of 200 mg/kg twice a day (II). VPA, given prior to transductions, was
shown to enhance the in vivo transduction efficacy based on beta-galactosidase staining of
frozen tumor sections. Nevertheless, VPA failed to reduce tumor growth either on its own
or in combination with TK+GCV, TMZ or combination of these compounds (Figure 11a,c,
II). However, adding VPA to TK+GCV with or without TMZ was able to enhance survival
of rats significantly compared to control group (Figure 11b). Furthermore, TK+GCV+TMZ
treated rats had significantly (33 %) increased survival in comparison to TK+GCV+VPA
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treatment and still 14 % increased survival compared to full combination of
TK+GCV+TMZ+VPA, although this was not statistically significant (II). TMZ and VPA were
both shown to cause thrombocytopenia and TMZ also leukocytopenia (II) being in line with
observations made in patients.
Figure 11. Effect of VPA on tumor volumes and survival of rats with MG. (a) Tumor volumes in
magnetic  resonance  imaging  (MRI)  at  day  28  and  42  post-inoculation  for  the  main  study
groups. Significances at day 42 are indicated. (b) Survival proportions of the same study groups
in  days  post-inoculation.  (c)  Representative  MRI  data  for  the  corresponding  groups.  Control,
non-operated  rats;  TK,  Ad.HSV-TK;  GCV,  ganciclovir;  TMZ,  temozolomide;  VPA,  sodium
valproate;  ND,  not  detected  (no  survivors  remaining);  ns,  non-significant.  *P<0.05  and
**P<0.01. Error bars = SEM.
The treatment protocol for TK+GCV+TMZ used in this study (14-day GCV with the last 5
days combined to TMZ) proved to be superior over a previously used protocol, where TMZ
was given separately from GCV (7-day GCV, 5-day gap, 5-day TMZ) resulting in a
significant benefit in tumor volumes (Figure 12a) as well as survival (Figure 12b).
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Figure 12. Comparison of treatment protocols. (a) Tumor volumes in magnetic resonance
imaging  (MRI)  at  day  28  and  42  post-inoculation  for  the  control  group  and  TK+GCV+TMZ
treatment groups with two separate protocols. (b) Survival proportions of the corresponding
groups  in  days  post-inoculation.  The  TK+GCV+TMZ  group  was  treated  with  GCV  for  14  days
including  TMZ  on  the  last  5  days.  The  TK+GCV+TMZ  (gap)  group  received  GCV  for  7  days
followed by a 5-day gap and then TMZ for the 5 following days. Otherwise treatment protocols
were  the  same.  Control,  non-operated  rats;  TK,  Ad.HSV-TK;  GCV,  ganciclovir;  TMZ,
temozolomide; ND, not detected (no survivors remaining); *P<0.05 and **P<0.01. Error bars
= SEM.
It has been claimed that HDIs are useful anticancer compounds as they have been shown to
enhance the efficacy of gene therapy, radiotherapy and chemotherapy (Chen et al. 2007, Fan
et al. 2005, Van Nifterik et al. 2012). On the other hand, HDIs have demonstrated both anti-
and protumorigenic properties and many of their effects are still unknown (Burgess et al.
2001, Gotfryd et al. 2010, Weller et al. 2011). Generally, they have been more efficient in
hematological malignancies where the dedifferentiation is a primary carcinogenic event
that  can be  reversed by the  epigenetic  functions  of  HDIs.  Success  in  solid  tumors  has  not
been so uniform (Wagner et al. 2010), and no general correlation has been reported between
VPA and survival of MG patients (Tsai et al. 2012, van Breemen et al. 2009).
VPA has been shown to impair the expression of Mgmt DNA repair gene sensitizing MG
cells to TMZ (Ryu et al. 2012). This mechanism could at least partially explain the enhanced
treatment effect observed with the combination of VPA and TMZ in vitro. VPA has also
been shown to increase CAR receptor expression and enhance AV-mediated gene
expression, which could explain the enhanced transduction efficiency in vitro.  Cx43  is  a
gap-junctional protein and therefore its relocation to cell junctions could enhance the
bystander effect through increased gap junctional communication of GCV metabolites
(Asklund et al. 2003, Asklund et al. 2004). The level of VPA stays more constant in vitro,
providing longer and more stable exposure and therefore better foundation for efficient
treatment responses, even when using physiological drug concentrations.
Modeling of the VPA responses in vivo has additional challenges such as reaching the
target cells with adequate concentrations and exposure time. Rodents have been shown to
eliminate VPA 10 times faster than humans (Chateauvieux et al. 2010, Stout et al. 2001), and
therefore, twice a day dosing may not have been frequent enough to maintain the
therapeutically effective concentrations although single value measurements were at a
desirable level. Other factors being responsible for the weak in vivo treatment response
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could have been the lower transduction efficiency compared to that observed in in vitro
experiments and unknown, possibly even protumorigenic responses originating from the
tumor microenvironment not present in vitro.
Despite the encouraging in vitro results,  VPA was not able to confer further benefits on
the TK+GCV+TMZ treatment combination in vivo. Nevertheless, the TK+GCV+TMZ
combination demonstrated clearly, for the first time, an in vivo survival benefit in
comparison to single treatments. The protocol for TK+GCV+TMZ used in this study proved
to be superior over its previous version with shorter GCV administration and non-
overlapping TMZ dosing. The encouraging results obtained with the current protocol (14-
day GCV with the last 5 days combined to TMZ) could be the basis for evaluating the
effects of simultaneous GCV and TMZ dosing in MG patients.
5.3  ToTK/AZT  –  AN  ALTERNATIVE  SUICIDE  GENE  THERAPY  FOR  MG
(III)
5.3.1 Substrate specificity and efficiency of suicide gene therapies in vitro
HSV-TK/GCV has been the most studied suicide gene therapy (Fillat et al. 2003, Maatta et
al. 2009). While it has proven to be safe, the lipophobicity of GCV and relatively low
enzymatic activity of HSV-TK hamper its efficacy (Khan et al. 2010). A novel suicide gene
therapy based on ToTK/AZT has demonstrated high enzymatic activity and substrate
specificity, as well as the beneficial lipophilicity of AZT would be considered to improve
drug BBB penetration (Denny 2003, Khan et al. 2010, Mutahir et al. 2011). This study
investigated whether ToTK/AZT could be used as an alternative to HSV-TK/GCV suicide
gene therapy. In vitro both enzymes,  HSV-TK and ToTK,  were  shown to  prefer  their  own
substrates, GCV and AZT respectively, in a concentration dependent manner in U87MG
(Figure 13a-b) as well as in U118MG human MG cells (III). A similar concentration
dependent viability reduction was also seen in murine glioma cells (BT4C and GL261) for
HSV-TK/GCV (Figure 13d, III) whereas ToTK showed no viability reduction with AZT
(Figure 13c, III). The highest concentrations of AZT and GCV were included as toxicity
controls in viability experiments. In the kinase activity measurements, ToTK exhibited the
high activity towards both deoxythymidine (dThd) and AZT in comparison to the minimal
activity seen with HSV-TK in U87MG. In BT4C rat glioma cells, no notable activity was
detected with either of the enzymes towards AZT or dThd (Figure 13e, III).
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Figure 13. Functionality of suicide gene therapies in vitro. Cell viabilities of U87MG human
glioma cells  after  AZT (a) and GCV (b),  and BT4C rat  glioma cells  after  AZT (c)  and GCV (d)
treatments. Cells were either nontransduced, transduced with either control vector or one of the
treatment  vectors.  Cell  viability  was  measured  by  the  MTS  assay.  Significances  compared  to
similarly  transduced  cells  with  no  nucleoside  analogue  are  shown.  (e)  For  kinase  activity
measurement cells were transduced as above and the enzymatic activity towards radiolabelled
dThd or AZT was measured at 48 h. Results are expressed in nanomoles of phosphorylated
substrate per minute per cell (nmol/min/cell). NT, nontransduced; Ctrl vector, transduced with
control vector containing no insert; ToTK, transduced with vector containing tomato thymidine
kinase; HSV-TK, transduced with vector containing Herpes Simplex virus-1 thymidine kinase;
AZT, azidothymidine; GCV, ganciclovir; dThd, deoxythymidine. *P<0.05; **P<0.01;
***P<0.001. Error bars = SEM.
5.3.2 No significant differences between suicide gene therapies in vivo
A preliminary in vivo experiment  was  conducted  to  establish  the  mouse  model,  to  set-up
the MRI monitoring and to determine the AZT concentration. The efficacies of suicide gene
therapies were then evaluated in nude mice intracranial glioma model by tumor growth
measurements and survival follow-up. The HSV-TK/GCV-treated tumors were the smallest
and grew the least according to consecutive MRI measurements (Figure 14a). A similar
trend was also seen with ToTK/AZT tumors. However, no statistically significant
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differences among groups were detected in tumor volumes (Figure 14a). The survival of
ToTK/AZT-treated mice was significantly (*P<0.05) longer than in the group of control mice
(Figure 14b). Survival of HSV-TK/GCV-treated mice was not significantly increased, but
half of the mice were still alive with detectable tumors at the end of the follow-up at day 70
post-inoculation. No significant differences were detected between the ToTK/AZT and
HSV-TK/GCV groups (Figure 14b). Macrophages were abundant in almost all tumors with
no clear correlation with the tumor size, the mode of the treatment or the survival time.
Figure 14. Functionality of suicide gene therapies in vivo. (a) Tumor volumes measured by MRI
at day 28 and 35 post-inoculation given in mm3 for different treatment groups. (b) Mice survival
proportions in days post-inoculation for the corresponding groups. Significance (*P<0.05) of
ToTK+AZT compared with Control is shown. Control, mice with no gene transfer or medication;
HSV-TK, Herpes Simplex virus-1 thymidine kinase; GCV, ganciclovir; ToTK, tomato thymidine
kinase; AZT, azidothymidine. Error bars = SEM.
The HSV-TK/GCV suicide gene system has been used for over two decades and
improvements have been made in order to enhance HSV-TK enzymatic activity towards
GCV. Splice-corrected versions and mutated variants have made it possible for less
immunosuppressive doses of GCV to be used (Black, Kokoris & Sabo 2001, Chalmers et al.
2001, Preuss et al. 2011). On the contrary, the potential benefits of tomato thymidine kinase
have been recognized only recently and further functional refinements still lie ahead. In this
study “native” enzymes were compared, both expressed from an identical AV vector. HSV-
TK and ToTK, were shown to prefer their own prodrugs, GCV and AZT respectively, with
only  marginal  activity  towards  the  other  prodrug.  Therefore,  although  impeding  the
comparison,  different  prodrugs were  used for  both enzymes in  order  to  achieve maximal
functionality.
Both HSV-TK and ToTK were shown to reduce cell viability with their preferred
prodrugs in human MG cells. However, only HSV-TK demonstrated the same activity in
murine MG cells. This was confirmed not only in the cell viability assessment but also in
kinase activity measurements where ToTK displayed no activity in rat glioma cells. The
explanation for this difference is so far unknown since it has previously been shown that
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murine  MG  cells  are  readily  transduced  with  AVs  (Stedt  et  al.  2013)  and  functionality  of
ToTK construct was proven in human MG cells.  As a result,  for the in vivo study, human
MG cells were chosen and this meant that an immunocompromised rodent model had to be
used. Although the orthotopic location made it possible to study the tumors in their natural
environment, the role of the intact immune system on tumor growth and treatments could
not be examined. In addition, possible interactions with tumor microenvironment of mouse
origin were likely influenced.
In vivo both of the suicide gene therapies exhibited the least tumor growth and the mice
showed a trend towards increased survival. However, only the survival of ToTK/AZT-
treated mice was statistically significantly longer than in control mice, with no statistical
differences being detected between the suicide gene therapies. There were no differences in
macrophage  immunostainings  in  terms  of  survival.  One  of  the  reasons  for  the  modest in
vivo treatment response could have been the limited transduction efficacy compared to the
in vitro situation. These constructs did not contain a marker gene and transduction efficacy
was not separately studied in the current experiment. However, this is a generally known
phenomenon which was also encountered in the first study of this thesis (Stedt et al. 2012).
Furthermore, the small number of mice per group (n = 5-7) could have reduced the power
to detect statistically significant differences.
Another aspect which needs to be considered is the concentration of nucleoside
analogues. The concentrations used in this study were chosen based on the previous
experience with GCV (Leinonen et al. 2012, Sandmair et al. 2000b, Tyynela et al. 2002) and
the published literature with AZT (Danesi et al. 1998, Dobrovolsky et al. 2005, Sato et al.
2007). However, although a preliminary experiment was carried out to determine a suitable
in vivo concentration for AZT, differences in experimental conditions in literature such as
the mouse strain may have affected the treatment outcome. It is known that the most
common adverse effects with GCV are neutropenia and thrombocytopenia (Denny 2003,
Faulds, Heel 1990). AZT has been well tolerated with low concentrations but high
concentrations have been shown to exert toxic effects e.g. hematotoxicity and hepatotoxicity
(Sato et al. 2007, Danesi et al. 1998). Therefore, full blood counts as well as liver and kidney
functions were analysed. No adverse effects were detected with the administered
treatments.
In this third study, neither of the treatments, HSV-TK/GCV or ToTK/AZT, demonstrated
clear superiority over the other. Both were found to be efficient in vitro while no significant
differences in in vivo efficacy were detected during the follow-up period. Therefore, it can
be concluded that ToTK/AZT is a potential alternative for HSV-TK/GCV treatment but
further comparative studies with increased animal numbers will be needed before more in
depth conclusions can be made.
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6 Summary and conclusions
The following conclusions can be made based on the individual studies (I-III) of this thesis:
I Src  is  a  key  player  in  tumorigenesis  and  a  potential  target  for  RNA
interference–mediated treatment of MG. Due to the limited gene transfer
efficacy in vivo and finite possibilities associated with single-target
treatments, Src shRNAs are proposed to be used as part of combination
therapies.
II Despite promising in vitro results,  VPA  did  not  further  enhance  the
therapeutic effect of the HSV-TK/GCV+TMZ combination in vivo. The
current protocol of administering TMZ simultaneously with the last five
days of 14-day GCV treatment following HSV-TK gene transfer restricted
the  tumor  growth  and  improved  rat  survival.  This  finding  may  be  of
potential clinical value for MG patients.
III ToTK/AZT  and  HSV-TK/GCV  were  shown  to  be  efficient  in  human  MG
cells,  and  the  latter  combination  also  in  rodent  MG  cells.  There  was  no
significant difference in the in vivo treatment efficacy observed between the
suicide gene therapies. ToTK/AZT is a potential alternative for HSV-
TK/GCV due to its beneficial therapeutic properties.
Traditional treatments of MG, surgery, radiotherapy and chemotherapy, are merely
palliative  for  GBM.  Due  to  the  infiltrative  growth  pattern  of  GBM,  complete  surgical
resection is practically impossible. Brain tumors are often resistant to radiotherapy and the
maximal dose for brain is 60 Gy, higher doses increase the risk of adverse effects without
confering any further therapeutic benefit. In addition to the toxicity of chemotherapy itself,
the BBB represents an obstacle to achieve sufficient concentrations within the treatable area.
For these reasons, alternative strategies including gene therapy are needed.
This thesis has explored alternative strategies as well as the combinations discussed
above. The different agents in combination therapies can exert different modes of action as
well as targeting different cellular functions. In addition, adverse effects may be reduced as
lower  drug  concentrations  or  doses  of  each  individual  drug  can  be  administered.  On  the
other hand, one should keep in mind that while increasing the number of different
therapies, the optimization of their administration protocols becomes more challenging and
there is an increasing possibility of unwanted interactions. Therefore, a careful preclinical
assessment of individual therapies and their combinations is a prerequisite before these
protocols can enter into clinical practice.
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Malignant glioma (MG) is a cancer 
with a dismal prognosis. Novel 
gene therapy strategies and their 
combinations with two clinically used 
drugs, temozolomide and valproate, 
were studied in preclinical in vitro 
and in vivo MG models. Src kinase was 
shown to be a key therapeutic target 
in gliomagenesis, and ToTK/AZT an 
alternative suicide gene therapy to 
HSV-TK/GCV. It is hoped that the 
new enhanced treatment schedule for 
HSV-TK/GCV with temozolomide will 
be of potential value for MG patients. 
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